<SEC-DOCUMENT>0001437749-26-004777.txt : 20260220
<SEC-HEADER>0001437749-26-004777.hdr.sgml : 20260220
<ACCEPTANCE-DATETIME>20260219195325
ACCESSION NUMBER:		0001437749-26-004777
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20260220
DATE AS OF CHANGE:		20260219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			cbdMD, Inc.
		CENTRAL INDEX KEY:			0001644903
		STANDARD INDUSTRIAL CLASSIFICATION:	PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				473414576
		STATE OF INCORPORATION:			NC
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292869
		FILM NUMBER:		26656248

	BUSINESS ADDRESS:	
		STREET 1:		8845 RED OAK BOULEVARD
		CITY:			CHARLOTTE
		STATE:			NC
		ZIP:			28217
		BUSINESS PHONE:		704-445-3060

	MAIL ADDRESS:	
		STREET 1:		8845 RED OAK BOULEVARD
		CITY:			CHARLOTTE
		STATE:			NC
		ZIP:			28217

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Level Brands, Inc.
		DATE OF NAME CHANGE:	20170202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEVEL BEAUTY GROUP, INC.
		DATE OF NAME CHANGE:	20150611
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ycbd20260218_s1a.htm
<DESCRIPTION>FORM S-1/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ycbd="http://www.cbdmd.com/20250930" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>ycbd20260218_s1a.htm</title>


	<!-- Generated by ThunderDome Portal - 2/20/2026 12:30:21 AM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:AmendmentFlag" id="ixv-2731">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityCentralIndexKey" id="ixv-2732">0001644903</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:DocumentType" id="c3">S-1/A</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="ycbd-20250930.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2024-10-01_2025-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001644903</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit></ix:resources>
</ix:header></div>
<div>&#160;</div>

<div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As filed with the Securities and Exchange Commission on February 19, 2026</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>&#160;Registration No. 333</b>-<b>292869</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PRE-EFFECTIVE AMENDMENT NO. 1</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <span style="-sec-ix-hidden:c3">S-1</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<div style="text-align: center;"><img alt="smlogo.jpg" src="smlogo.jpg"/></div>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityRegistrantName" id="c4">cbdMD, Inc.</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant As Specified In Its Charter)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityIncorporationStateCountryCode" id="c5" format="ixt-sec:stateprovnameen">North Carolina</ix:nonNumeric></b></p>
			</td>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2833</b></p>
			</td>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityTaxIdentificationNumber" id="c6">47-3414576</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State Or Other Jurisdiction Of Incorporation Or Organization)</p>
			</td>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Primary Standard Industrial<br/>
			Classification Code Number)</p>
			</td>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer<br/>
			Identification Number)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityAddressAddressLine1" id="c7">2101 Westinghouse Blvd.</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Suite A</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityAddressCityOrTown" id="c8">Charlotte</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityAddressStateOrProvince" id="c9">NC</ix:nonNumeric> <ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityAddressPostalZipCode" id="c10">28273</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:CityAreaCode" id="c11">704</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:LocalPhoneNumber" id="c12">445-3060</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address, Including Zip Code, And Telephone Number, Including Area Code, Of Registrant&#8217;s Principal Executive Offices)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>T. Ronan Kennedy</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Executive Officer and Chief Financial Officer</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2101 Westinghouse Blvd.</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Suite A</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Charlotte, NC 28273</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(704) 445-3060 </b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name, Address, Including Zip Code, And Telephone Number, Including Area Code, Of Agent for Service)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">COPIES TO:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Brian A. Pearlman, Esq.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Brian S. Bernstein, Esq.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Nason Yeager Gerson Harris &amp; Fumero P.A.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>3001 PGA Blvd., Suite 305</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Palm Beach Gardens, Florida 33410</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(561) 686-3307</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">As soon as practicable after this Registration Statement becomes effective.</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: &#9746;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is used to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Large accelerated filer</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accelerated filer</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityFilerCategory" id="c13" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160;</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Smaller reporting company</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntitySmallBusiness" id="c14" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Emerging growth company</p>
			</td>
			<td style="vertical-align:middle;width:auto;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:EntityEmergingGrowthCompany" id="c15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><ix:nonNumeric contextRef="d_2024-10-01_2025-09-30" name="dei:AmendmentDescription" id="c16">The registrant hereby amends this registration statement on such date or date(s) as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until the registration statement shall become effective on such date as the SEC acting pursuant to said Section 8(a) may determine.</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) of which this prospectus is a part becomes effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Subject to Completion, dated February 19, 2026</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROSPECTUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>cbdMD, Inc.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2,000,000&#160;Shares of Common Stock </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This prospectus relates to the potential resale from time to time of up to 2,000,000 shares of our common stock (the &#8220;Shares&#8221;) by the selling shareholders identified herein (the &#8220;Selling Shareholders&#8221;). The Shares being offered by the Selling Shareholders are issuable upon conversion of shares of our Series C Convertible Preferred Stock (&#8220;Series C Preferred Stock&#8221;), and possible initial dividend payments, which were sold and issued to the Selling Shareholders pursuant to separate Preferred Stock Purchase Agreements, dated as of December 18, 2025, by and between us and the Selling Shareholders (collectively, the &#8220;Purchase Agreements&#8221;). Such registration does not mean that the Selling Shareholders will actually offer or sell any of these shares. We will not receive any proceeds from the sales of the shares of our common stock by the Selling Shareholders being registered hereby.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our common stock is listed on the NYSE American under the symbol &#8220;YCBD.&#8221; On February 19, 2026, the last reported sales price of our common stock on the NYSE American was $0.7234&#160;per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><span style="color:#ff00ff;">The Selling Shareholders and any broker-dealers or agents that are involved in selling the Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act <span style="text-decoration: underline; ">of 1933 (the "Securities Act")</span>&#160;in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Shareholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</span></p>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">You should read this prospectus and any prospectus supplement or amendment, together with additional information described under the headings &#8220;Where You Can Find More Information,&#8221; carefully before you invest in our securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading </b>&#8220;<b><i>Risk Factors</i></b>&#8221;<b> beginning on page 5 of this prospectus, and under similar headings in any amendment or supplement to this prospectus or in any other documents incorporated by reference into this prospectus.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The date of this prospectus is February 19, 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">About This Prospectus</p>
			</td>
			<td style="vertical-align: top; width: auto; text-align: center;">1</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cautionary Statement Regarding Forward Looking Statements</p>
			</td>
			<td style="vertical-align: top; width: auto; text-align: center;">1</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prospectus Summary</p>
			</td>
			<td style="vertical-align: top; width: auto; text-align: center;">2</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Offering</p>
			</td>
			<td style="vertical-align: top; width: auto; text-align: center;">4</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk Factors</p>
			</td>
			<td style="vertical-align: top; width: auto; text-align: center;">5</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Private Placement</p>
			</td>
			<td style="vertical-align: top; width: auto; text-align: center;">6</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Use of Proceeds</p>
			</td>
			<td style="vertical-align: top; width: auto; text-align: center;">7</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Determination of Offering Price</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Market Information</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Selling Shareholders</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Plan of Distribution</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Business</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Description of Capital Stock</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Properties</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Legal Proceedings</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Directors, Executive Officers and Corporate Governance</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Compensation</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain Relationships and Related Transactions and Director Independence</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Legal Matters</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Experts</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Where You Can Find More Information</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">15</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporation of Certain Information by Reference</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">15</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ABOUT THIS PROSPECTUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus is part of a registration statement that we have filed with the SEC pursuant to which the Selling Shareholders named herein may, from time to time, offer and sell or otherwise dispose of the securities covered by this prospectus. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the Information Incorporated by Reference herein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Neither we nor the Selling Shareholders have authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about, and to observe, any restrictions as to the offering and the distribution of this prospectus applicable to those jurisdictions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We further note that the representations, warranties and covenants made in any agreement that is filed as an exhibit to any document that is incorporated by reference in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information in this prospectus is accurate as of the date on the front cover. Information incorporated by reference into this prospectus is accurate as of the date of the document from which the information is incorporated. You should not assume that the information contained in this prospectus is accurate as of any other date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unless the context otherwise indicates, when used in this report, the terms the &#8220;Company,&#8221; &#8220;cbdMD, &#8220;we,&#8221; &#8220;us, &#8220;our&#8221; and similar terms refer to cbdMD, Inc., a North Carolina corporation, and our subsidiaries CBD Industries LLC, a North Carolina limited liability company formerly known as cbdMD LLC, which we refer to as &#8220;CBDI,&#8221;&#160;Paw CBD, Inc., a North Carolina corporation which we refer to as &#8220;Paw CBD&#8221; and cbdMD Therapeutics LLC, a North Carolina limited liability company which we refer to as &#8220;Therapeutics&#8221; and Proline Global, LLC a North Carolina limited liability company which we refer to as &#8220;Proline Global.&#8221; In addition, &#8220;fiscal 2025&#8221; refers to the year ended September 30, 2025, and &#8220;fiscal 2024&#8221; refers to the year ended September 30, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus includes forward-looking statements including, but not limited to, statements regarding our liquidity, anticipated capital expenditures, and expected sales to the Selling Shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All statements contained in this prospectus other than statements of historical facts, including but not limited to statements regarding our future financial position, liquidity, business strategy, plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; and elsewhere in this prospectus and in our filings with the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect events or circumstances after the date on which such statements were made or to reflect the occurrence of unanticipated events, except as may be required by applicable securities laws.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROSPECTUS SUMMARY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>This summary highlights information contained elsewhere in this prospectus or incorporated by reference. It may not contain all of the information that you should consider before investing in our securities. You should read this entire prospectus carefully, including the </i>&#8220;<i>Risk Factors</i>&#8221;<i> section, and the financial statements and related notes included or incorporated by reference herein. This prospectus includes forward-looking statements that involve risks and uncertainties. See </i>&#8220;<i>Cautionary Statement Regarding Forward-Looking Statements.</i>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corporate Information</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our company was formed under the laws of the state of North Carolina in March 2015 under the name Level Beauty Group, Inc. In November 2016 we changed the name of our company to Level Brands, Inc. Effective May 1, 2019, we changed our name to cbdMD, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our principal executive offices are located at 2101 Westinghouse Blvd., Suite A Charlotte, NC 28273. Our telephone number at this location is (704) 445-3060. Our corporate website address is www.cbdmd.com. The information contained in, and that can be accessed through, our websites or our various social media platforms is not incorporated into and is not a part of this prospectus.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Company </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We own and operate the nationally recognized CBD (cannabidiol) brands cbdMD, Paw CBD, and Bluebird Botanicals <span style="text-decoration: underline; ">("Bluebird")</span>, as well as functional mushroom brand ATRx Labs, and Herbal Oasis (&#8220;Oasis&#8221;), our line of THC beverages,&#160;We believe that we are an industry leader producing and distributing hemp derived solutions including broad spectrum CBD products and full spectrum CBD products. Our mission is to enhance our customer&#8217;s overall quality of life while bringing powerful natural plant education, awareness and accessibility of high quality and effective products to all. We source hemp-derived cannabinoids, which are extracted from non-GMO hemp grown on farms in the United States. Our innovative broad spectrum formula utilizes one of the purest hemp extracts, containing CBD, CBG and CBN, while eliminating the presence of tetrahydrocannabinol (THC). Non-THC is defined as below the level of detection using validated scientific analytical methods. Our full spectrum and Delta 9 products contain a variety of cannabinoids and terpenes in addition to CBD while maintaining small amounts of THC that fall below the level of detection and are&#160;within the limits set in the 2018 Farm Act. In addition to our core brands, we also operate cbdMD Therapeutics&#160;to capture the Company&#8217;s ongoing investments in science related to its existing and future products, including research and development activities for therapeutic applications.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our cbdMD brand of products includes an array of high-grade, premium every day and functional CBD products, including tinctures; gummies; topicals; capsules; and sleep, focus and calming aids.&#160;In addition, we have clinical based claims and industry leading strength and concentrations to drive product efficacy.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our Paw CBD brand of products includes veterinarian-formulated products including tinctures, chews, and topical products in varying strengths and formulas. Paw CBD products have undergone the National Animal Safety Council&#8217;s rigorous audit and meet their Quality Seal standard.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our ATRx brand was developed using the power of functional mushrooms to provide consumers a complementary natural ingredient solution for immunity, focus, digestive health, and cognitive and mood benefits.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Oasis is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Bluebird Botanicals&#160;is a line of premium full spectrum CBD Products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">cbdMD, Paw CBD, Oasis, Bluebird and ATRx products are distributed through our e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Recent Developments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Management continues to be very focused on our goal of delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During the first quarter, legislation continued to be a key factor impacting the industry. On November 12, 2025, President Trump signed into law H.R. 5371, the &#8220;Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026&#8221; (the &#8220;Act&#8221;), which makes continuing appropriations and extensions for fiscal year 2026, and which also limits any THC content to 0.4mg per container for hemp-derived consumable products nationally effective November 12, 2026. It is unknown to the Company whether or not the sections of the Act that impact the hemp industry will ultimately go into effect on November 12, 2026, or if those sections will be replaced, impacted or amended by subsequent acts of Congress. While cbdMD was founded using THC-free broad spectrum formulations, a significant amount of our revenues are derived from products that contain low-dose hemp-derived THC that complies with the original Farm Bill. The Act, if implemented as currently written, will in all likelihood have a material adverse impact on the Company&#8217;s business, results of operations, and financial condition. The majority of the Company&#8217;s revenue for the three months ended December 31, 2025 were derived from products that would comply with the Act's THC limitations, however a meaningful amount of revenue could be impacted should no changes in legislation occur. Management is actively monitoring this legislation and evaluating strategic alternatives to mitigate potential impacts, but there can be no assurance that the Company will be able to successfully adapt its product portfolio or that alternative legislation will be enacted. During December 2025, Senator Wyden introduced the Cannabinoid Safety and Regulation Act (&#8220;CSRA&#8221;) which has received strong support from industry and a number of legislators, and would mitigate damaging impact for the Act, should this be ultimately signed into law. On January 22, 2026, the Hemp Enforcement, Modernization, and Protection (&#8220;HEMP&#8221;) Act was filed in Congress lead by bi-partisan support. As of the date of this filing, there are no assurance that the CSRA or HEMP will be enacted. Additionally, we continue to see changing rules and regulation at the state level which is causing some disruption and additional costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Toward the end of the first quarter of 2026, the Company raised additional cash to bolster its balance sheet with the Series C Preferred Stock and structured an <span style="text-decoration: underline; ">equity line of credit ("ELOC")</span>. Over the last few months, we have seen several instances where the stock price and volume spiked and ELOC&#160;will allow us to prudently take advantage of these situations should they occur in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has continued to pursue several potential acquisitions since the conversion of the Series A Preferred Stock in 2025. In January 2026, the Company acquired the Bluebird Botanicals brand. The Company believes Bluebird provides (i) a large existing customer base that we believe is underserved with their existing product portfolio (ii) a brand name not defined by CBD, allowing for natural expansion into other natural products, (iii) significant SG&amp;A savings, (iv) intellectual property&#160;including self-GRAS status on their full spectrum product and (v) an estimated $600,000 in revenue per quarter with opportunities to grow. We believe this revenue, once fully integrated, can provide a step function in our growth and have a meaningful impact on non-GAAP&#160;EBITDA and Net Income</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We remain focused on growing the Company in a smart, profitable manner along with appropriate cost controls.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>The Private Placement Transaction</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On December 18, 2025, the Company entered into the Purchase Agreements with the Selling Shareholders whereby the Company sold and issued to the Selling Shareholders an aggregate of 1,000,000 shares of Series C Preferred Stock in exchange for aggregate gross proceeds totaling $2,250,000. The Company has used and/or intends to use the proceeds from the issuance of the Series C Preferred Stock for working capital and general corporate purposes. The Series C Preferred Stock was initially convertible at $2.25 per share, and pursuant to the Series C Certificate of Designation, as amended by a Letter Agreement dated February 10, 2026, is adjusted to $1.13 per share upon the effectiveness of the registration statement which includes this prospectus, covering the conversion shares, and further subject to adjustment as provided in the Series C Preferred Stock Certificate of Designation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, on December 18, 2025, the Company and the Selling Shareholders entered into the Registration Rights Agreements (the &#8220;Registration Rights Agreements&#8221;), pursuant to which the Company agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Series C Preferred Stock sold and issued to the Selling Shareholders under the Purchase Agreements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In no event shall we issue any shares of common stock upon conversion of the Series C Preferred Stock to the extent that after giving effect thereto, the aggregate number of shares of common stock that would be issued pursuant to the Purchase Agreements would exceed 19.99% of the total number of shares of common stock issued and outstanding immediately preceding the execution of the Purchase Agreements (1,782,990 shares) (the &#8220;Exchange Cap&#8221;), subject to adjustment as set forth in the Purchase Agreements, unless and until we obtain the approval of the issuance of such shares by our shareholders in accordance with the NYSE American.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>THE OFFERING</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus relates to the resale by the Selling Shareholders identified in this prospectus of up to 2,000,000 shares of common stock (the &#8220;Shares&#8221;). The Selling Shareholders may sell their Shares from time to time at market prices prevailing at the time of sale, at prices related to the prevailing market price, or at negotiated prices. We will not receive any proceeds from the sale of Shares by the Selling Shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common stock offered by the Selling Shareholders</b></p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Up to 2,000,000 shares of our common stock, assuming full conversion of the Series C Preferred Stock at a conversion price equal to $1.13&#160;per share.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">&#160;</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common stock outstanding immediately prior to this offering</b></p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10,495,561 shares.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">&#160;</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common stock outstanding immediately following this offering</b></p>
			</td>
			<td style="vertical-align:top;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">12,495,561 shares, assuming full conversion of the Series C Preferred Stock at a conversion price equal to $1.13 per share.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">&#160;</td>
			<td style="vertical-align:top;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Terms of the offering</b>&#160;</p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Selling Shareholders will determine when and how it will dispose of any shares of our common stock that are registered under this prospectus for resale. See &#8220;Plan of Distribution.&#8221;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of proceeds</b></p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Selling Shareholders will receive all of the proceeds from the sale of the Shares offered for sale by it under this prospectus. See &#8220;Use of Proceeds&#8221;&#160;on page 9&#160;for more information.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">&#160;</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Stock Symbol</b></p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">YCBD</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">&#160;</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:37.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Transfer Agent and Registrar</b></p>
			</td>
			<td style="vertical-align:middle;width:1.5%;">&#160;</td>
			<td style="vertical-align:middle;width:37.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">VStock Transfer, LLC</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>The following summary contains basic information about this offering. The summary is not intended to be complete. You should read the full text and more specific details contained elsewhere in this prospectus.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Outstanding Shares</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The number of shares of our common stock to be outstanding after this offering assumes 10,495,561 shares of our common stock outstanding as of February 19, 2026, and excludes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a total of 591,207 shares of common stock issuable upon the conversion of Series B Preferred Stock at $1.00 per share;</p>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a&#160;total of 2,000,000 shares of common stock issuable upon conversion of Series C Convertible Preferred Stock at $1.13 per share;</p>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a total of 19,716 shares of common stock issuable upon vesting of unvested restricted stock awards and 445,000 shares of unvested restricted common stock granted under the Company&#8217;s 2025 Equity Incentive Plan which is subject to shareholder approval;</p>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a total of 5,517 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $991.71 per share;</p>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a total of 5,901 shares of common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price of $208.75 per share; and</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a total of 525,000 shares of common stock issuable as earnout shares.</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Unless otherwise indicated, all information in this prospectus assumes no exercise or settlement of outstanding options or warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RISK FACTORS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Investing in our securities involves risks. Before purchasing the securities offered by this prospectus you should carefully read the risk factors incorporated by reference in this prospectus from our Annual Report on Form 10-K for the year ended September 30, 2025 filed with the SEC on December 19, 2025, as well as the risks, uncertainties and additional information set forth in the other documents incorporated by reference in this prospectus that we file with the SEC after the date of this prospectus and which are deemed incorporated by reference in this prospectus, and the information contained in any applicable prospectus supplement. For a description of these reports and documents, and information about where you can find them, see &#8220;Incorporation of Certain Information by Reference.&#8221; The risks and uncertainties we discuss in this prospectus and in the documents incorporated by reference in this prospectus are those that we currently believe may materially affect our company. Additional risks not presently known, or currently deemed immaterial, also could materially and adversely affect our financial condition, results of operations, business and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are subject to the continued listing standards of the NYSE American and our failure to satisfy these criteria may result in de-listing of our securities.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our common stock is listed on the NYSE American. In order to maintain these listings, we must maintain certain share prices, financial and share distribution targets, including maintaining a minimum amount of shareholders&#8217; equity and a minimum number of public shareholders. In addition to these objective standards, the NYSE American may delist the securities of any issuer (i) if, in its opinion, the issuer&#8217;s financial condition and/or operating results appear unsatisfactory; (ii) if it appears that the extent of public distribution or the aggregate market value of the security has become so reduced as to make continued listing on the NYSE American inadvisable; (iii) if the issuer sells or disposes of principal operating assets or ceases to be an operating company; (iv) if an issuer fails to comply with the NYSE American&#8217;s listing requirements; (v) if an issuer&#8217;s securities sell at what the NYSE American considers a &#8220;low selling price&#8221; and the issuer fails to correct this via a reverse split of shares after notification by the NYSE American; or (vi) if any other event occurs or any condition exists which, in the opinion of the NYSE American, makes continued listing inadvisable. If the NYSE American delists our common stock, investors may face material adverse consequences, including, but not limited to, a lack of trading market for our securities, reduced liquidity, decreased analyst coverage of our securities, and an inability for us to obtain any additional financing to fund our operations that we may need.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may use proceeds from the Purchase Agreements in ways with which you may not agree or in ways which may not yield a significant return.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will have broad discretion over the use of proceeds from sales of our Series C Preferred Stock made pursuant to the Purchase Agreements, including for any of the purposes described in the section entitled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds from this offering as set forth in &#8220;Use of Proceeds,&#8221; we are not obligated to do so. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The issuance of shares upon exercise of our outstanding options, restricted stock awards and warrants, or the conversion of the Series B and Series C Preferred Stock (or preferred stock dividends paid in shares of common stock) may cause immediate and substantial dilution to our existing shareholders.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We presently have options, unvested restricted stock awards and warrants that if exercised would result in the issuance of an additional 31,134&#160;shares of our common stock and 445,000&#160;shares of unvested and unissued restricted common stock granted under the Company&#8217;s 2025 Equity Incentive Plan which is subject to shareholder approval. Our Series B Preferred Stock is currently convertible into 591,207&#160;shares of common stock. Our Series C Preferred Stock is currently convertible into 2,000,000 shares of common stock. We also presently have 525,000 shares of common stock issuable subject to an earnout. The issuance of shares upon exercise of warrants and options, vesting of restricted awards and/or the conversion of shares of our Series B or Series C Preferred Stock (or preferred stock dividends paid in shares of common stock) will result in dilution to the interests of other shareholders. Further, as it relates to the Series B Preferred Stock, upon the effectiveness of a registration statement registering the resale by the holders of the registrable securities, the conversion price shall equal the lower of (a) the original conversion price or (b) the closing price of the common stock on effective date of such registration statement. The Series B and Series C Preferred Stock are subject to anti-dilution adjustments and price protection provisions, which may be triggered upon the issuance of common stock, options or convertible securities at a price below the then-applicable conversion price, and Alternate Conversion Rights (as defined in the Series B and Series C Certificate of Designations) resulting from a Triggering Event (as defined in the Series B or Series C Certificate of Designations).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>THE PRIVATE PLACEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On December 18, 2025, the Company entered into the Purchase Agreements with the Selling Shareholders pursuant to which the Company sold and issued 1,000,000 shares of Series C Preferred Stock in exchange for aggregate gross proceeds totaling $2,250,000. The Company has used and/or intends to use the proceeds from the sale and issuance of the Series C Preferred Stock for working capital and general corporate purposes. On December 19, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the &#8220;Series C Certificate of Designation&#8221;) designating 1,000,000 shares of the Company&#8217;s authorized preferred stock as Series C Convertible Preferred Stock, par value $0.001 per share and stated value of $2.25 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Each share of Series C Preferred Stock is convertible into shares of our common stock at a conversion price of $1.13 per share at any time at the option of the holder and further subject to certain adjustments (the &#8220;Conversion Price&#8221;). If the Company grants, issues or sells shares of common stock at a price (the &#8220;New Issuance Price&#8221;) that is less than the then-current Conversion Price, the Conversion Price will automatically be reduced to equal such New Issuance Price, subject to the floor price limitations. The Series C Preferred Stock Conversion Price is subject to adjustments for stock splits, stock dividends, stock combinations, recapitalizations and similar events or subject to compliance with the rules and regulations of the NYSE American and is&#160;subject to anti-dilution adjustments and price protection provisions, which may be triggered upon the issuance of common stock, options or convertible securities at a price below the then-applicable conversion price, and Alternate Conversion rights (as defined in the Series C Certificate of Designation) resulting from a Triggering Event (as defined in the Series C Certificate of Designation).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Series C Preferred Stock accrues dividends at a rate of 10% per annum which are payable quarterly in shares of common stock, subject to the satisfaction of all Equity Conditions (as defined in the Certificate of Designation), or in cash. If the Company fails to satisfy an Equity Condition, dividends shall be paid in cash. However, if North Carolina law prohibits the payment of dividends in cash, then the Stated Value (as defined in the Certificate of Designation) shall be increased by the amount of such unpaid dividends, with such increase to be determined in accordance with procedures mutually agreed upon between the Company and the holders of the Series C Preferred Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">With respect to dividends, distributions, liquidation, dissolution and winding up of the Company, the Series C Preferred Stock ranks pari passu with the Series B Preferred Stock and is senior to all other shares of the Company&#8217;s capital stock unless otherwise consented to by the holders of the Series C Preferred Stock. The holders of Series C Preferred Stock have no voting power and no right to vote, except as required by the North Carolina Business Corporations Act or with respect to matters affecting the preferences, rights, privileges or powers relating to the Series C Preferred Stock. In addition, the Series C Preferred Stock is subject to a beneficial ownership limitation which prohibits any holder from beneficially owning more than 4.99% of the shares of the Company&#8217;s common stock outstanding immediately following such conversion. The Series C Certificate of Designation contains various restrictive covenants and protective provisions, including restrictions on the Company&#8217;s ability to incur additional indebtedness, redeem capital stock, pay cash dividends, dispose of assets outside of the ordinary course of business or make certain issuances of securities. The complete rights, preferences and limitations of the Series C&#160;Preferred Stock are set forth in the Series C Certificate of Designation. The Company and the holders of the Series C Preferred Stock entered into the Letter Agreement date February 10, 2026 amending the Series C Certificate of Designation to (i) provide for a fixed conversion price of $1.13 per share, and (ii) eliminate price reset mechanisms that would otherwise apply in the event of the filing of any additional registration statement covering conversion shares. The Letter Agreement did not remove the price protection for non-exempt issuances at prices below $1.13 or Alternate Conversions.&#160;As of February 12, 2026, there are 1,000,000 shares of Series C Preferred Stock outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under applicable NYSE American Company Guide rules and as set forth in the Purchase Agreements, in no event may we issue to the Selling Shareholders shares of our common stock, upon conversion of the Series C Preferred Stock, representing 20% or more of the total number of shares of common stock outstanding immediately prior to the date of the Purchase Agreements (1,782,990 shares) unless we obtain prior stockholder approval or if such approval is not required in accordance with the applicable NYSE American rules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the Purchase Agreements, the Company agreed to reimburse the Selling Shareholders in an amount of $15,000 for all costs and expenses incurred by the Selling Shareholders or their affiliates in connection with the private placement transactions between the Company and the Selling Shareholders. Also, pursuant to the Registration Rights Agreements, the Company agreed to pay all fees and expenses in connection with registration of the Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Purchase Agreements and Registration Rights Agreements contain customary registration rights, representations, warranties, conditions and indemnification obligations by each party. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and are subject to certain important limitations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The foregoing description of the Purchase Agreements and Registration Rights Agreements and the transactions contemplated thereby does not purport to be complete and are qualified in their entirety by reference to the form of Purchase Agreements and form of Registration Rights Agreement, a copy of which were filed as Exhibits 10.22 and 10.23, respectively, to the Company&#8217;s Annual Report Form 10-K on December 19, 2025 and is incorporated by reference to the registration statement of which this prospectus forms a part.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>No Short-Selling or Hedging</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Shareholders have agreed that neither it nor any entity managed or controlled by it will engage in, directly or indirectly, any (A) &#8220;short sale&#8221; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or (B) hedging transaction, which, with respect to items (A) and (B), establishes a net short position with respect to the common stock, during the term of the Purchase Agreements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The issuance of our shares of common stock to the Selling Shareholders pursuant to the Purchase Agreements will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted. Although the number of shares of common stock that our existing stockholders own will not decrease, the shares of common stock owned by our existing stockholders will represent a smaller percentage of our total outstanding shares of common stock after any such issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>USE OF PROCEEDS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus relates to shares of our common stock that may be offered and sold from time to time by Selling Shareholders. We will not receive any proceeds from the resale of shares of common stock by the Selling Shareholders. All proceeds we received from sale and issuance of the Series C Preferred Stock will be used for working capital and general corporate purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DETERMINATION OF OFFERING PRICE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Each Selling Shareholder will determine at what price(s) such Selling Shareholder may sell the Shares, and such sales may be made at prevailing market prices, or at privately negotiated prices.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MARKET INFORMATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our common stock is listed on the NYSE American under the symbol &#8220;YCBD.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On February 19, 2026, the last reported sale price of our common stock on the NYSE American was $0.7234&#160;per share. As of February 19, 2026, we had approximately 117 stockholders of record. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>THE SELLING SHAREHOLDERS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus relates to the possible resale from time to time by the Selling Shareholders of any or all shares of our common stock that have been or may be issued by us to the Selling Shareholders under the Purchase Agreements upon conversion of the Series C Preferred Stock. We are registering the shares of common stock underlying the Series C Preferred Stock pursuant to the provisions of the Registration Rights Agreements in order to permit the Selling Shareholders to offer the shares for resale from time to time. Except for the transactions contemplated by the Purchase Agreements and the Registration Rights Agreements, the Selling Shareholders have not had any material relationship with us within the past three years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As used in this prospectus, the term &#8220;Selling Shareholders&#8221; includes the Selling Shareholders listed in the table below, and their permitted pledgees, donees, transferees, assignees, successors, designees, successors-in-interest and others who later come to hold any of the Selling Shareholders&#8217; interests in the shares of common stock in accordance with the terms of the applicable agreements governing their respective registration rights, other than through a public sale. This prospectus also covers any additional securities that may become issuable by reason of stock splits, stock dividends or other similar transactions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The table below presents information regarding the Selling Shareholders and the shares of common stock that they may offer from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Shareholders, and reflects holdings as of February 19, 2026. The number of shares in the column &#8220;Number of Shares of Common Stock Owned Prior to Offering&#8221; includes the shares of common stock to be issued to the Selling Shareholders upon conversion of the Series C Preferred Stock at the current Conversion Price of $1.13 and subject to the Beneficial Ownership Limitation. The number of shares in the column &#8220;Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus&#8221; represents all of the shares of common stock that the Selling Shareholders may offer under this prospectus based on a number of the Shares which may be received upon conversion of the Series C Preferred Stock at a conversion price of $1.13. The Selling Shareholders may sell some, all or none of their shares in this offering. We do not know how long the Selling Shareholders will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Shareholders regarding the sale of any of the shares. In no event shall we issue or sell any shares of common stock pursuant to the Purchase Agreements to the extent that after giving effect thereto, the aggregate number of shares of common stock that would be issued pursuant to the Purchase Agreements would exceed 19.99% of the total number of shares of common stock issued and outstanding immediately preceding the execution of the Purchase Agreements (the &#8220;Exchange Cap&#8221;), subject to adjustment as set forth in the Purchase Agreements, unless and until we obtain the approval of the issuance of such shares by our shareholders in accordance with the NYSE American.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which the Selling Shareholders have voting and investment power. The percentage of common stock beneficially owned by the Selling Shareholders prior to the offering shown in the table below is based on an aggregate of 10,495,561 shares of our common stock outstanding on February 2, 2026. The column &#8220;Number of Shares of Common Stock Owned After Offering&#8221; assumes the sale of all of the shares offered by the Selling Shareholders pursuant to this prospectus. In addition, the Series C Preferred Stock is subject to a beneficial ownership limitation which prohibits any holder from beneficially owning more than 4.99% of the shares of the Company&#8217;s common stock outstanding immediately following such conversion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Please see the section titled &#8220;<i>Plan of Distribution</i>&#8221; for further information regarding the Selling Shareholders&#8217; method of distributing these securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name of Selling </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Shareholder</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of Shares of</b><br/>
			<b>Common Stock Owned</b><br/>
			<b>Prior to Offering</b></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Maximum </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares of </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Common </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Stock to be </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Offered </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Pursuant to </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>this </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Prospectus</b></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of Shares</b><br/>
			<b>of Common Stock Owned After </b></b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Offering</b></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Percent</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Percent</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">C/M Capital Master Fund, LP (1)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">523,728</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,466,666</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color: #ff00ff; ">354,722</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color: #ff00ff; ">2.8</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">WVP Emerging Manager Onshore Fund, LLC - C/M Capital Series (2)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color: #ff00ff; ">523,728</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">533,334</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,948</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The business address of C/M Capital Master Fund, LP is 1111 Brickell Avenue, Suite 2920, Miami, Florida 33131. As of the date of the Purchase Agreement, C/M Capital Master Fund, LP did not beneficially own any shares of our common stock. Thomas Walsh and Jonathan Juchno are the Managing Partners of C/M Capital Master Fund, LP, and therefore may be deemed to have shared voting and investment power over securities owned directly and indirectly by C/M Capital Master Fund, LP. The amount of shares beneficially owned by the Selling Shareholder consists of shares of common stock issuable upon conversion of 354,722 shares of Series B Preferred Stock, shares of common stock issuable upon conversion of 733,333&#160;shares of Series C Preferred Stock, subject to Beneficial Ownership Limitation and excludes any shares of common stock that the Company may sell, in its sole discretion, to C/M Capital Master Fund, LP under the ELOC Agreement. C/M Capital Master Fund, LP is not a registered broker-dealer or an affiliate of a registered broker-dealer. The foregoing should not be construed in and of itself as an admission by Mr. Walsh and Mr. Juchno as to beneficial ownership of the securities beneficially owned directly or indirectly by C/M Capital Master Fund, LP. Shares of common stock issuable upon conversion of Series B Preferred Stock and shares issuable under the ELOC Agreement are subject to a beneficial ownership limitation which prohibits any holder from beneficially owning more than 4.99% of the shares of the Company&#8217;s common stock.</p>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
			</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The business address of WVP Emerging Manager Onshore Fund, LLC &#8211; C/M Capital Series is Two Executive Drive, Suite 515 Fort Lee, New Jersey 07024. Thomas Walsh is the managing member of WVP Emerging Manager Onshore Fund, LLC &#8211; C/M Capital Series and has voting control and investment discretion over securities beneficially owned directly by WVP Emerging Manager Onshore Fund, LLC &#8211; C/M Capital Series. The amount of shares beneficially owned by the Selling Shareholder consists of shares of common stock issuable upon conversion of 137,948 shares of Series B Preferred Stock and shares of common stock issuable upon conversion of 266,667 shares of Series C Preferred Stock. We have been advised that none of Mr. Walsh or WVP Emerging Manager Onshore Fund, LLC &#8211; C/M Capital Series is a member of the Financial Industry Regulatory Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Mr. Walsh as to beneficial ownership of the securities beneficially owned directly by WVP Emerging Manager Onshore Fund, LLC &#8211; C/M Capital Series. Shares of common stock issuable upon conversion of Series B Preferred Stock are subject to a beneficial ownership limitation which prohibits any holder from beneficially owning more than 4.99% of the shares of the Company&#8217;s common stock.</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PLAN OF DISTRIBUTION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The shares of common stock offered by this prospectus are being offered by the Selling Shareholders. The shares may be sold or distributed from time to time by the Selling Shareholders directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of our common stock offered by this prospectus could be effected in one or more of the following methods:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">ordinary brokers&#8217;&#160;transactions;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">transactions involving cross or block trades;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">through brokers, dealers, or underwriters who may act solely as agents;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;at the market&#8221;&#160;into an existing market for our common stock;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">in privately negotiated transactions;&#160;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">any combination of the foregoing; or</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">any other method permitted pursuant to applicable law.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s registration or qualification requirement is available and complied with.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Shareholders may be deemed to be &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Shareholders have informed us that they intend to use one or more registered broker-dealers to effectuate all sales, if any, of our common stock that they have acquired and may in the future acquire from us pursuant to the Purchase Agreements. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. The Selling Shareholders have informed us that each such broker-dealer will receive commissions from the Selling Shareholders that will not exceed customary brokerage commissions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Brokers, dealers, underwriters or agents participating in the distribution of our common stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Shareholders through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of our common stock sold by the Selling Shareholders may be less than or in excess of customary commissions. Neither we nor the Selling Shareholders can presently estimate the amount of compensation that any agent will receive from any purchasers of our common stock sold by the Selling Shareholders.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We know of no existing arrangements between the Selling Shareholders or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of our common stock offered by this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by the Selling Shareholders, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by the Selling Shareholders, any compensation paid by the Selling Shareholders to any such brokers, dealers, underwriters or agents, and any other required information.&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will pay the expenses incident to the registration under the Securities Act of the offer and sale of our common stock covered by this prospectus by the Selling Shareholders. We have also paid the Selling Shareholders $15,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by the Selling Shareholders, including the legal fees and disbursements of the Selling Shareholders&#8217; legal counsel, in connection with their due diligence investigation of the Company and in connection with the preparation, negotiation and execution of the Purchase Agreements. See &#8220;<i>The Private Placement</i>&#8221; for more information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We also have agreed to indemnify the Selling Shareholders and certain other persons against certain liabilities in connection with the offering of our common stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. The Selling Shareholders have agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by the Selling Shareholders specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Selling Shareholders have represented to us that at no time prior to the date of the Purchase Agreements have the Selling Shareholders or their agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock. The Selling Shareholders have agreed that during the term of the Purchase Agreements, neither the Selling Shareholders, nor any of their agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have advised the Selling Shareholders that they are required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Shareholders, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company shall use its commercially reasonable efforts to have the registration statement and any amendment declared effective by the SEC at the earliest practicable date. The Company shall use commercially reasonable efforts to keep the registration statement effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the Selling Shareholder of all of the registrable securities covered thereby at all times until the date on which the Selling Shareholder shall have resold all the registrable securities covered thereby and no shares of common stock remain issuable under the Purchase Agreements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This offering will terminate on the date that all of our common stock offered by this prospectus have been sold by the Selling Shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our discussion and analysis of financial condition and results of operations is incorporated by reference from Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K beginning on Page 21, as filed with the SEC on December 19, 2025, as amended. (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BUSINESS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The description of our business is incorporated by reference from Part I, Item 1 of the Company&#8217;s Annual Report on Form 10-K beginning on Page 4, as filed with the SEC on December 18, 2025, as amended (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DESCRIPTION OF CAPITAL STOCK</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>The following description summarizes important terms of our capital stock and our other securities. For a complete description, you should refer to our Articles of Incorporation and bylaws, forms of which are incorporated by reference to the exhibits to the registration statement of which this prospectus is a part.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our authorized capital is 150,000,000 shares of common stock, par value $0.001 per share, and 50,000,000 shares of blank check preferred stock, par value $0.001 per share. We have designated 1,700,000 of our blank check preferred stock as Series B Convertible Preferred Stock and 1,000,000 of our blank check preferred stock as Series C Convertible Preferred Stock. On February 19, 2026, there were 591,207 shares of Series B Convertible Preferred Stock&#160;<span style="text-decoration: underline; ">("Series B Preferred Stock")</span>&#160;and 1,000,000 shares of Series C Convertible Preferred Stock issued and outstanding. The balance of the blank check preferred stock is undesignated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Common Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Holders of common stock are entitled to one vote for each share on all matters submitted to a shareholder vote. Holders of common stock do not have cumulative voting rights. Holders of common stock are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available funds. In the event of our liquidation, dissolution or winding up, subject to the preferences of any shares of our preferred stock which may then be outstanding, each outstanding share entitles its holder to participate in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Holders of common stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions for the common stock. The rights of the holders of common stock are subject to any rights that may be fixed for holders of preferred stock, when and if any preferred stock is authorized and issued. All outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of February 2, 2026, we had 10,495,561 shares of common stock outstanding. In addition, as of that date, there were approximately 19,716 shares of common stock issuable upon vesting of unvested restricted stock awards; 5,517 shares of common stock issuable upon the exercise of outstanding stock options; 5,901 shares of common stock issuable upon the exercise of outstanding warrants; 525,000 shares of common stock issuable under an earnout; 445,000 shares of unvested and unissued restricted common stock granted under the Company&#8217;s 2025 Equity Incentive Plan which is subject to shareholder approval; 591,207 shares of common stock issuable upon conversion of our Series B Preferred Stock outstanding and 1,000,000 shares of common stock issuable upon conversion of our Series C Preferred Stock outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Preferred Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our board of directors, without further shareholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Series B Convertible Preferred Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On September 29, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the &#8220;Series B Certificate of Designation&#8221;) designating 1,700,000 shares of the Company&#8217;s authorized preferred stock as Series B Convertible Preferred Stock, par value $0.001 per share and stated value of $1.00 per share. Each share of the Series B Preferred Stock is initially convertible into common stock at a conversion price of $1.00, subject to anti-dilution adjustments and price protection provisions, which may be triggered upon the issuance of common stock options or convertible securities at a price below the then-applicable conversion price, and Alternate Conversion rights (as defined in the Series B Certificate of Designation) resulting from a Triggering Event (as defined in the Series B Certificate of Designation). The Series B Preferred Stock accrues dividends at a rate of 10% per annum which are payable quarterly in shares of common stock, subject to the satisfaction of all Equity Conditions (as defined in the Series B Certificate of Designation), or in cash. If the Company fails to satisfy an Equity Condition, dividends shall be paid in cash. However, if North Carolina law prohibits the payment of dividends in cash, then the then Stated Value (as defined in the Series B Certificate of Designation) shall be increased by the amount of such unpaid dividends. The Series B Preferred Stock is further subject to repricing adjustments upon the effectiveness of a registration statement wherein the conversion price shall equal the lower of the (a) original conversion price or (b) the closing price of the common stock on the effective date of such registration statement. Additionally, the Series B Preferred Stock is subject to rights for adjustments for more favorable terms&#160;upon any issuance by the Company, or subsidiaries, of any security in a future financing&#160;with terms more favorable than those set forth in the Series B Certificate Designation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">With respect to dividends, distributions, liquidation, dissolution and winding up of the Company, the Series B Preferred Stock ranks pari passu with the Series C Preferred Stock and is senior to all other shares of the Company&#8217;s capital stock unless otherwise consented to by the holders of the Series B Preferred Stock. The holders of Series B Preferred Stock have no voting power and no right to vote, except as required by the North Carolina Business Corporations Act or with respect to matters affecting the preferences, rights, privileges or powers relating to the Series B Preferred Stock. In addition, the Series B Preferred Stock is subject to a beneficial ownership limitation which prohibits any holder from beneficially owning more than 4.99% of the shares of the Company&#8217;s common stock outstanding immediately following such conversion. The Series B Certificate of Designation contains various restrictive covenants and protective provisions, including restrictions on the Company&#8217;s ability to incur additional indebtedness, redeem capital stock, pay cash dividends, dispose of assets outside of the ordinary course of business or make certain issuances of securities. The complete rights, preferences and limitations of the Series B Preferred Stock are set forth in the Series B Certificate of Designation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series C Convertible Preferred Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On December 19, 2025, the Company filed the Series C Certificate of Designation designating 1,000,000 shares of the Company&#8217;s authorized preferred stock as Series C Convertible Preferred Stock, par value $0.001 per share and stated value of $2.25 per share. Except for differences in the stated value, floor price and conversion price, the Series C Preferred Stock has terms and conditions that are substantially similar to those of the Company&#8217;s Series B Preferred Stock. Each share of the Series C Preferred Stock is convertible into common stock at a conversion price of $2.25, and pursuant to the Series C Certificate of Designation, as amended by a Letter Agreement dated February 10, 2026, is adjusted to $1.13 per share upon the effectiveness of a registration statement covering the conversion shares, and further subject to anti-dilution adjustments and Alternate Conversion rights (as defined in the Series C Certificate of Designation) resulting from a Triggering Event (as defined in the Series C Certificate of Designation). The Series C Preferred Stock accrues dividends at a rate of 10% per annum which are payable quarterly in shares of common stock, subject to the satisfaction of all Equity Conditions (as defined in the Series C Certificate of Designation), or in cash. If the Company fails to satisfy an Equity Condition, dividends shall be paid in cash. However, if North Carolina law prohibits the payment of dividends in cash, then the then Stated Value (as defined in the Series C Certificate of Designation) shall be increased by the dividends as reasonably determined by the Company and the holders of the Series C Preferred Stock. Additionally, the Series C Preferred Stock is subject to rights for adjustments for more favorable terms&#160;upon any issuance by the Company, or subsidiaries, of any security in a future financing,&#160;with terms more favorable than those set forth in the Series C Certificate Designation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">With respect to dividends, distributions, liquidation, dissolution and winding up of the Company, the Series C Preferred Stock ranks pari passu with the Series B Preferred Stock and is senior to all other shares of the Company&#8217;s capital stock unless otherwise consented to by the holders of the Series C Preferred Stock. The holders of Series C Preferred Stock have no voting power and no right to vote, except as required by the North Carolina Business Corporations Act or with respect to matters affecting the preferences, rights, privileges or powers relating to the Series C Preferred Stock. In addition, the Series C Preferred Stock is subject to a beneficial ownership limitation which prohibits any holder from beneficially owning more than 4.99% of the shares of the Company&#8217;s common stock outstanding immediately following such conversion. The Series C Certificate of Designation contains various restrictive covenants and protective provisions, including restrictions on the Company&#8217;s ability to incur additional indebtedness, redeem capital stock, pay cash dividends, dispose of assets outside of the ordinary course of business or make certain issuances of securities. The complete rights, preferences and limitations of the Series C Preferred Stock are set forth in the Series C Certificate of Designation which is attached as Appendix C to this proxy statement. The Company and the holders of the Series C Preferred Stock entered into a Letter Agreement dated February 10, 2026 amending the Series C Certificate of Designation to (i) provide for a fixed conversion price of $1.13 per share, and (ii) eliminate price reset mechanisms that would otherwise apply in the event of the filing of any additional registration statement covering conversion shares. The Letter Agreement did not remove the price protection for non-exempt issuances at prices below $1.13 or Alternate Conversions. As of February 19, 2026, there are 1,000,000 shares of Series C Preferred Stock outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Warrants</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of February 19, 2026, we have outstanding warrants to purchase 5,901 shares of common stock with exercise prices ranging from $20.16 to $1,350.00 and expiration dates from June 2026 to April 2028. The terms of the outstanding warrants were disclosed in the Company&#8217;s Current Reports on Form 8-K filed with the SEC on June 30, 2021 and May 3, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Listings</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our common stock is listed on the NYSE American under the symbol &#8220;YCBD.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Transfer Agent</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The transfer agent for our common stock is VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Disclosure of Commission Position on Indemnification for Securities Act Liabilities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROPERTIES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The description of our properties is incorporated by reference from Part I, Item 2 of the Company&#8217;s Annual Report on Form 10-K beginning on page 19, as filed with the SEC on December 19, 2025 (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LEGAL PROCEEDINGS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The description of our legal proceedings is incorporated by reference from Part I, Item 3 of the Company&#8217;s Annual Report on Form 10-K beginning on Page 19 as filed with the SEC on December 19, 2025, as amended (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The description of directors, executive officers and corporate governance is incorporated by reference from the Company&#8217;s definitive proxy statement on Schedule 14A beginning on page 23 filed with the SEC on February 12, 2026 (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXECUTIVE COMPENSATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The description of our executive compensation is incorporated by reference form the Company&#8217;s definitive proxy statement on Schedule 14A beginning on page 26 filed with the SEC on February12, 2026 (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The description of our security ownership of beneficial owners and management is incorporated by reference from the Company&#8217;s definitive proxy statement on Schedule 14A beginning on page 31 filed with the SEC on February 12, 2026 (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The description of certain relationships and related transactions and director independence is incorporated by reference from the Company&#8217;s definitive proxy statement on Schedule 14A beginning on page 32 filed with the SEC on February 12, 2026 (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LEGAL MATTERS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The validity of the securities offered hereby will be passed upon for us by Gavigan Law, PLLC, Charlotte, North Carolina.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPERTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The consolidated financial statements of cbdMD, Inc. and our subsidiaries for the years ended September 30, 2025 and 2024, have been audited by Cherry Bekaert LLP, independent registered public accounting firm, as set forth in their report thereon appearing in cbdMD, Inc.&#8217;s Annual Report on Form 10-K for the year ended September 30, 2025, and incorporated by reference herein. Such consolidated financial statements are incorporated by reference herein in reliance upon such report, which includes an explanatory paragraph on cbdMD, Inc. and our subsidiaries&#8217; ability to continue as a going concern, given on the authority of such firm as experts in accounting and auditing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We file annual, quarterly, and other reports, proxy statements and other information with the SEC. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge on our website and through the SEC&#8217;s Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at https://www.sec.gov. You may access the registration statement, of which this prospectus is a part, at the SEC&#8217;s website.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We make available through our website, free of charge, copies of our SEC filings as soon as reasonably practicable after we electronically file or furnish them to the SEC on our website, https://www.cbdmd.com. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus forms part of a registration statement we have filed with the SEC relating to, among other things, the common stock. As permitted by SEC rules, this prospectus does not contain all the information we have included in the registration statement and the accompanying exhibits and schedules we have filed with the SEC. You may refer to the registration statement, exhibits and schedules for more information about us and the common stock. The statements this prospectus makes pertaining to the content of any contract, agreement or other document that is an exhibit to the registration statement necessarily are summaries of their material provisions, and we qualify them in their entirety by reference to those exhibits for complete statements of their provisions. The registration statement, exhibits and schedules are available through the SEC&#8217;s website.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at <i>www.sec.gov</i>. The SEC allows us to &#8220;incorporate by reference&#8221; the information in certain documents that we file with it, which means that we can disclose important information to you by referring you to documents previously filed with the SEC. The information incorporated by reference is considered to be part of this prospectus, and the information that we subsequently file with the SEC will automatically update and supersede this information. This prospectus incorporates by reference the Company&#8217;s documents listed below and all documents subsequently filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of the offering of the securities described in this prospectus (other than documents or information deemed to have been furnished and not filed in accordance with SEC rules, unless otherwise expressly incorporated by reference herein):</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#9679;&#160;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Annual Report on Form 10-K for Fiscal Year ended September 30, 2025 filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001644903/000143774925038435/ycbd20250930_10k.htm" style="-sec-extract:exhibit;">December 19, 2025</a>, as amended on Form 10-K/A filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001644903/000143774926001542/ycbd20250930_10ka.htm" style="-sec-extract:exhibit;">January 20, 2026</a>;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our Quarterly Report on Form 10-Q for the period ended December 31, 2025 filed with the SEC on February 17, 2026;</td>
		</tr>
		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#9679;&#160;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our current reports on Form 8-K (including 8-K/A) filed on (including 8-K/A) filed on <a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925036342/ycbd20251120_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">November 25, 2025</span></a>, <a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925036497/ycbd20251128_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">November 28, 2025</span></a>,&#160;<a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925037156/ycbd20251208_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">December 8, 2025</span></a>&#160;and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001644903/000143774926001219/ycbd20260113_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">January 14, 2026</span></a>&#160;(other than information furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits relating to such information, which is neither filed nor incorporated by reference herein); and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">&#9679;&#160;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our definitive proxy statement on Schedule 14A filed on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001644903/000143774926003831/ycbd20260209_def14a.htm" style="-sec-extract:exhibit;">February 12, 2026</a>.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, was furnished, rather than filed, with the SEC, that information or exhibit is specifically not incorporated by reference in this document.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">You may obtain copies of these documents free of charge on our website, www.cbdmd.com, as soon as reasonably practicable after they have been filed with the SEC and through the SEC&#8217;s website, www.sec.gov. You may also obtain such documents by submitting a written request either to the Company at 2101 Westinghouse Blvd., Suite A, Charlotte, NC 28273, Attention: T. Ronan Kennedy or an oral request by calling the Company at (704) 445-3060. The Company will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the reports that have been incorporated by reference in the prospectus contained in the registration statement but not delivered with the prospectus upon oral or written request, at no cost to the requester, by contacting the Company as noted above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>PROSPECTUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>cbdMD, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Offering of&#160;2,000,000</b>&#160;<b>shares of common stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>_______ __, 2026</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION NOT REQUIRED IN THE PROSPECTUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 13. Other Expenses of Issuance and Distribution.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table sets forth the costs and expenses payable by us in connection with the issuance and distribution of the securities being registered hereunder. All of the amounts shown are estimates, except for the SEC registration fees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SEC registration fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">226.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Printing expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounting fees and expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal fees and expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Miscellaneous</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">72,726.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 2px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 14. Indemnification of Directors and Officers.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Sections 55-8-50 through 55-8-58 of the North Carolina General Statutes permit a corporation to indemnify its directors, officers, employees or agents under either or both a statutory or non-statutory scheme of indemnification. Under the statutory scheme, a corporation may, with certain exceptions, indemnify a director, officer, employee or agent of the corporation who was, is, or is threatened to be made, a party to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative, or investigative, because of the fact that such person was a director, officer, agent or employee of the corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. This indemnity may include the obligation to pay any judgment, settlement, penalty, fine (including an excise tax assessed with respect to an employee benefit plan) and reasonable expenses incurred in connection with a proceeding (including counsel fees), but no such indemnification may be granted unless such director, officer, agent or employee (i) conducted himself in good faith, (ii) reasonably believed (a) that any action taken in his official capacity with the corporation was in the best interest of the corporation or (b) that in all other cases his conduct at least was not opposed to the corporation&#8217;s best interest, and (iii) in the case of any criminal proceeding, had no reasonable cause to believe his conduct was unlawful. Whether a director has met the requisite standard of conduct for the type of indemnification set forth above is determined by the board of directors, a committee of directors, special legal counsel or the shareholders in accordance with Section 55-8-55. A corporation may not indemnify a director under the statutory scheme in connection with a proceeding by or in the right of the corporation in which the director was adjudged liable to the corporation or in connection with a proceeding in which a director was adjudged liable on the basis of having received an improper personal benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to, and separate and apart from the indemnification described above under the statutory scheme, Section&#160;55-8-57 of the North Carolina General Statutes permits a corporation to indemnify or agree to indemnify any of its directors, officers, employees or agents against liability and expenses (including attorney&#8217;s fees) in any proceeding (including proceedings brought by or on behalf of the corporation) arising out of their status as such or their activities in such capacities, except for any liabilities or expenses incurred on account of activities that were, at the time taken, known or believed by the person to be clearly in conflict with the best interests of the corporation. Our bylaws provide for indemnification to the fullest extent permitted by law for persons who serve as a director, officer, agent or employee of cbdMD or at the request of cbdMD serve as a director, officer, agent or employee for any other corporation, partnership, joint venture, trust or other enterprise, or as a trustee or administrator under an employee benefit plan. Accordingly, we may indemnify our directors, officers, agents or employees in accordance with either the statutory or non-statutory standards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Sections 55-8-52 and 55-8-56 of the North Carolina General Statutes require a corporation, unless its articles of incorporation provide otherwise, to indemnify a director or officer who has been wholly successful, on the merits or otherwise, in the defense of any proceeding to which such director or officer was a party. Unless prohibited by the articles of incorporation, a director or officer also may make application and obtain court-ordered indemnification if the court determines that such director or officer is fairly and reasonably entitled to such indemnification as provided in Sections 55-8-54 and 55-8-56.&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">II-1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Finally, Section 55-8-57 of the North Carolina General Statutes provides that a corporation may purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the corporation against certain liabilities incurred by such persons, whether or not the corporation is otherwise authorized by the North Carolina Business Corporation Act to indemnify such party. We have purchased a standard directors&#8217; and officers&#8217; liability policy which will, subject to certain limitations, indemnify us and our officers and directors for damages they become legally obligated to pay as a result of any negligent act, error, or omission committed by directors or officers while acting in their capacity as such.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As permitted by North Carolina law, Article 6 of our Articles of Incorporation limits the personal liability of directors for monetary damages for breaches of duty as a director arising out of any legal action for breach of duty as a director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Insofar as the limitation of, or indemnification for, liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, or persons controlling us pursuant to the foregoing, or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such limitation or indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">See also the undertakings set out in response to Item 17 herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 15. Recent Sales of Unregistered Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A summary of all securities that we have sold in the last year, since the beginning of the last fiscal year without registration under the Securities Act, is incorporated by reference from Part II, Item 5 of the Company&#8217;s Annual Report on Form 10-K as filed with the SEC on December 19, 2025, the Company&#8217;s Quarterly Report on Form 10-Q as filed with the SEC on February 17, 2026 and the Company&#8217;s current report on Form 8-K filed on October 6, 2025 and January 14, 2026 (see &#8220;Incorporation of Certain Information by Reference&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 16. Exhibits and Financial Statement Schedules</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(a) See the Exhibit Index on the page immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form S-1, which Exhibit Index is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(b) No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the notes thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 17. Undertakings </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The undersigned registrant hereby undertakes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(i) To include any prospectus required by section 10(a)(3) of the Securities Act;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">II-2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(4) That, for the purpose of determining liability under the Securities Act to any purchaser:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <i>Provided</i>, <i>however</i>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(5) That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(6) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to any charter provision, by law or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">II-3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXHIBIT INDEX</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The following documents are being filed with the SEC as exhibits to this registration statement on Form S-1.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b><br/>
			<b>No.</b></p>
			</td>
			<td style="vertical-align:bottom;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit Description</b></p>
			</td>
			<td style="vertical-align:bottom;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p>
			</td>
			<td style="vertical-align:bottom;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filing </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
			<td style="vertical-align:bottom;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>No.</b></p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filing or </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Furnished </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Herewith</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774923012366/ex_511758.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Underwriting Agreement, dated as of April 30, 2023, between cbdMD, Inc. and Maxim Group LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/3/23</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495418013530/levb_ex2-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Merger Agreement dated December 3, 2018 by and among Level Brands, Inc., AcqCo, LLC, cbdMD LLC and Cure Based Development, LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/3/18</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.2</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495419001576/level_ex2-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Merger dated December 20, 2018 as filed with the Secretary of State of Nevada merging AcqCo, LLC with and into Cure Based Development, LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/14/19</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.2</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.3</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495419001576/level_ex2-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Merger dated December 20, 2018 as filed with the Secretary of State of North Carolina merging AcqCo, LLC with and into Cure Based Development, LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/14/19</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.3</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.4</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495419001576/level_ex2-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Merger dated December 20, 2018 as filed with the Secretary of State of Nevada merging Cure Based Development, LLC with and into cbdMD LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/14/19</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.4</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.5</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495419001576/level_ex2-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Merger dated December 20, 2018 as filed with the Secretary of State of North Carolina merging Cure Based Development, LLC with and into cbdMD LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/14/19</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.5</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.6</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495421003778/ycbd_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Addendum No. 1 to Agreement and Plan of Merger dated March 31, 2021</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/1/21</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Incorporation</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex22.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment to the Articles of Incorporation - filed April 22, 2015</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.2</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex23.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment to the Articles of Incorporation - filed June 22, 2015</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.3</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex24.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment to the Articles of Incorporation - filed November 17, 2016</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.4</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.5</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex25.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment to the Articles of Incorporation - filed December 5, 2016</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.5</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.6</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495419004936/levb_ex37.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment to Articles of Incorporation</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/29/19</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.7</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.7</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495419011679/ycbd_31f.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment to Articles of Incorporation including the Certificate of Designations, Rights and Preferences of the 8.0% Series A Cumulative Convertible Preferred Stock</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/11/19</p>
			</td>
			<td style="vertical-align:bottom;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1(f)</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.8</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774923011231/ex_507592.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment of Articles of Incorporation, as amended, of cbdMD, Inc. effective April 24, 2023</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/27/23</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.9</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925015119/ex_813151.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment Automatic Conversion of Series A Preferred Stock effective May 6, 2025</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/7/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.10</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925015119/ex_813152.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Articles of Amendment to the Articles of Incorporation 8 to 1 reverse split effective May 6, 2025</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/7/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.2</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.11</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925030537/ex_866201.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Designation of Series B Convertible Preferred Stock filed September 29, 2025</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/6/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.12</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925038435/ex_901129.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Designation of Series C Convertible Preferred Stock filed December 19, 2025</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/19/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.12</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.13</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex26.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Bylaws, as amended</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.6</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex38.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2015 Equity Compensation Plan+</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.8</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex39.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Stock Option Award under 2015 Equity Compensation Plan*</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.9</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495421000468/ycbd_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2021 Equity Compensation Plan*</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/14/21</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495420000297/ycbd_ex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Representative</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Warrant dated January 9, 2020</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/10/20</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495420013331/ycbd_ex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Representative</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Warrant dated December 11, 2020</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/9/20</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495421007411/ycbd_ex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Representative</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Warrant dated June 28, 2021</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/30/21</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">II-4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.7</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774923012366/ex_511759.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Representative</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Warrant dated May 3, 2023</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/3/23</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.8</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774924002975/ex_621911.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Convertible Promissory Note dated January 30, 2024</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/2/24</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.9</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925036497/ex_893883.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2025 Equity Compensation Plan*</span></a></p>
			</td>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:top;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/28/25</p>
			</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Opinion of Gavigan Law, PLLC</p>
			</td>
			<td style="vertical-align:middle;width:3%;">&#160;</td>
			<td style="vertical-align:middle;width:4.5%;">&#160;</td>
			<td style="vertical-align:middle;width:4%;">&#160;</td>
			<td style="vertical-align: middle; width: 5.5%; text-align: center;">(1)</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495417008542/level_ex621.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Indemnification Agreement</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1-A</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/18/17</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6.21</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.2</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495419009562/ycbd_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Office Lease dated July 11, 2019</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/14/19</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.3</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495420001499/ycbd_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Warehouse Lease dated August 27, 2019</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/13/20</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.4</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495420002069/ycbd_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Distribution Agreement dated February 26, 2020 by and among cbdMD, Inc., CBD Holdings, LLC and the members of CBD Holdings, LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/28/20</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.5</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495420008894/ycbd_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Endorsement Agreement effective July 1, 2020</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/21/20</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.6</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495421008238/ycbd_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Asset Purchase Agreement by and among Twenty Two Capital, LLC, cbdMD, Inc., John J. Wiesehan III, Vieo Design, LLC and Bradley D. Trawick dated June 22, 2021</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/27/21</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.7</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495421010818/ycbd_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Executive Employment Agreement dated October 1, 2021 between cbdMD, Inc. and T. Ronan Kennedy*</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/5/21</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.8</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925036497/ex_893882.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Executive Employment Agreement dated November 28, 2025 between cbdMD, Inc and T. Ronan Kennedy*+</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/28/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.9</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495422006755/ycbd_ex1021.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Equipment Purchase Agreement effective April 7, 2022 by and between cbd Industries, LLC and Old Belts Extracts LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/7/22</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.21</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.10</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774922020140/ex_410604.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Membership Interest Transfer Agreement dated June 22, 2022</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/11/22</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.22</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.11</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774923006378/ex_485900.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement for Advertising Placement dated February 1, 2023+</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">S-1</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/13/23</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.17</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.12</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774923006378/ex_487228.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Side Letter </span><span style="text-decoration: underline; ">&#8211;</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Keystone Capital Partners, LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">S-1</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/13/23</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.20</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.13</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774923005246/ex_482976.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Common Stock Purchase Agreement dated March 2, 2023 by and among cbdMD, Inc. and Keystone Capital Partners, LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/2/23</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.14</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774923005246/ex_482977.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement dated March 2, 2023 by and among cbdMD, Inc. and Keystone Capital Partners, LLC</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/2/23</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.15</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774924008153/ex_640353.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">License Agreement, effective as of March 20, 2024, by and between cbdMD, Inc. and HSKL, Inc.</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/18/24</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.16</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774924008153/ex_640354.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lease Forbearance Agreement, dated as of March 14, 2024, by and between cbdMD, Inc. and HSKL, Inc.</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/18/24</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.17</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774924036298/ex_752761.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Extend Westinghouse Boulevard Lease dated November 26, 2024</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/27/24</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.18</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925030537/ex_866173.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Preferred Stock Purchase Agreement between cbdMD, Inc. and the Selling Shareholders+</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/6/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.19</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925030537/ex_866174.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Registration Rights Agreement between cbdMD, Inc. and the Selling Shareholders</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/6/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.20</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925038435/ex_901131.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Securities Purchase Agreement by and between cbdMD, Inc. and C/M Capital Master Fund, LP, dated December 15, 2025, as amended</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/19/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.20</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.21</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925038435/ex_901132.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement by and between cbdMD, Inc. and C/M Capital Master Fund, LP, dated December 15, 2025</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/19/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.21</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.22</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925038435/ex_901133.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Series C Preferred Stock Securities Purchase Agreement dated December 19, 2025</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/19/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.22</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.23</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774925038435/ex_901134.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Registration Rights Agreement date December 19, 2025</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/19/25</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.23</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">10.24</td>
			<td style="vertical-align:top;width:34%;"><a href="http://www.sec.gov/Archives/edgar/data/0001644903/000143774926001219/ex_907169.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Asset Purchase Agreement by and among cbdMD, Inc., Gaia Botanicals, LLC d/b/a Bluebird Botanicals, CBD CliniLabs LLC, and Precision Botanical LLC company dated January 12, 2026+</span></a></td>
			<td style="vertical-align: middle; width: 3%; text-align: center;">8-K</td>
			<td style="vertical-align: middle; width: 4.5%; text-align: center;">1/14/26</td>
			<td style="vertical-align: middle; width: 4%; text-align: center;">10.1</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">10.25</td>
			<td style="vertical-align:top;width:34%;"><a href="http://www.sec.gov/Archives/edgar/data/0001644903/000143774926001219/ex_907184.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lockup Agreement Gaia Botanicals, LLC and cbdMD, Inc., dated January 12, 2026</span></a></td>
			<td style="vertical-align: middle; width: 3%; text-align: center;">8-K</td>
			<td style="vertical-align: middle; width: 4.5%; text-align: center;">1/14/26</td>
			<td style="vertical-align: middle; width: 4%; text-align: center;">10.2</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774926004343/ex_921177.htm" style="-sec-extract:exhibit;">10.26</a></td>
			<td style="vertical-align:top;width:34%;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000143774926004343/ex_921177.htm" style="-sec-extract:exhibit;">Letter Agreement between cbdMD, Inc. and Series C Preferred Shareholders dated February 10, 2026</a></td>
			<td style="vertical-align: middle; width: 3%; text-align: center;">10-Q</td>
			<td style="vertical-align: middle; width: 4.5%; text-align: center;">2/17/26</td>
			<td style="vertical-align: middle; width: 4%; text-align: center;">10.11</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1644903/000165495421013292/ycbd_ex211.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">List of Subsidiaries</span></a></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">S-1</p>
			</td>
			<td style="vertical-align:middle;width:4.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/16/24</p>
			</td>
			<td style="vertical-align:middle;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">21.1</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_923049.htm" style="-sec-extract:exhibit;">Consent of Cherry Bekaert LLP</a></p>
			</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:bottom;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:middle;width:5.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Filed</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.2</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Consent of Gavigan Law, PLLC (contained in Exhibit 5.1)</p>
			</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</p>
			</td>
			<td style="vertical-align:top;width:34%;">Inline XBRL Instance Document.</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</p>
			</td>
			<td style="vertical-align:top;width:34%;">Inline XBRL Taxonomy Extension Schema Document.</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</p>
			</td>
			<td style="vertical-align:top;width:34%;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</p>
			</td>
			<td style="vertical-align:top;width:34%;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</p>
			</td>
			<td style="vertical-align:top;width:34%;">Inline XBRL Taxonomy Extension Label Linkbase Document.</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</p>
			</td>
			<td style="vertical-align:top;width:34%;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p>
			</td>
			<td style="vertical-align:top;width:34%;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td>
			<td style="vertical-align:top;width:3%;">&#160;</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">107</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Filing Fee Table</p>
			</td>
			<td style="vertical-align:top;width:3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:4.5%;">&#160;</td>
			<td style="vertical-align:top;width:4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(1)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">+ Certain schedules, appendices and exhibits to this agreement have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished supplementally to the Securities and Exchange Commission staff upon request.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">* Management contract or compensatory plan or arrangement.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(1) Previously filed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">II-5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Charlotte, State of North Carolina on February 19, 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
			<td colspan="2" style="vertical-align:middle;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>CBDMD, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:auto;">&#160;</td>
			<td style="vertical-align:middle;width:auto;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">/s/</span><i><span style="text-decoration: underline; ">T. Ronan Kennedy</span></i></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">T. Ronan Kennedy</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: bottom; width: 21%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ T. Ronan Kennedy</span></i></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">T. Ronan Kennedy</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Executive Officer, Chief Financial Officer, Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ Brad Whitford</span></i></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Brad Whitford</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Accounting Officer (Principal Accounting Officer)</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ Scott G. Stephen</span></i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chairman of the Board of Directors</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Scott G. Stephen</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">&#160;</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ Jeffrey Porter </span></i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jeffrey Porter</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ William F. Raines</span></i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">William F. Raines</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ Kevin Roe</span></i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Kevin Roe</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ Bakari Sellers</span></i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Bakari Sellers</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">&#160;</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">/s/ Dr. Sibyl Swift</span></i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%; text-align: center;">February 19, 2026</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dr. Sibyl Swift</p>
			</td>
			<td style="vertical-align: middle; width: 2%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: top; width: 2%;">&#160;</td>
			<td style="vertical-align: top; width: 21%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">II-6</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex_923049.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_923049.htm</title>

	<!-- Generated by ThunderDome Portal - 2/19/2026 10:02:41 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We consent to the incorporation by reference in this Registration Statement of cbdMD, Inc., and Subsidiaries on Form S-1/A to be filed on or about February 19, 2026 of our report dated December 19, 2025, on our audits of the financial statements as of September 30, 2025 and 2024 and for each of the years then ended, which report was included in the Annual Report on Form 10-K filed December 19, 2025. Our report contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern. We also consent to reference to us under the heading &#8220;Experts&#8221; in such registration statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ Cherry Bekaert LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cherry Bekaert LLP </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Charlotte, North Carolina</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 19, 2026</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ycbd-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:30AM UTC 2026-02-20--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ycbd="http://www.cbdmd.com/20250930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cbdmd.com/20250930">
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ycbd-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ycbd-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ycbd-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.cbdmd.com/20250930/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ycbd_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="ycbd_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="ycbd_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="ycbd_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>ycbd-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:30AM UTC 2026-02-20--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.cbdmd.com/20250930/role/statement-document-and-entity-information" xlink:href="ycbd-20250930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cbdmd.com/20250930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ycbd-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:30AM UTC 2026-02-20--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="ycbd-20250930.xsd#ycbd_DocumentAndEntityInformation" xlink:label="ycbd_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="ycbd_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ycbd_DocumentAndEntityInformation" xlink:to="ycbd_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="ycbd-20250930.xsd#ycbd_NotesToFinancialStatements" xlink:label="ycbd_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="ycbd_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ycbd_NotesToFinancialStatements" xlink:to="ycbd_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="ycbd-20250930.xsd#ycbd_NotesToFinancialStatementsAbstract" xlink:label="ycbd_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="ycbd_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ycbd_NotesToFinancialStatementsAbstract" xlink:to="ycbd_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="ycbd-20250930.xsd#ycbd_NoteToFinancialStatementDetailsTextual" xlink:label="ycbd_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="ycbd_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ycbd_NoteToFinancialStatementDetailsTextual" xlink:to="ycbd_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AmendmentDescription</link:label>
    <link:label xlink:label="dei_AmendmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ycbd-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 12:30AM UTC 2026-02-20--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cbdmd.com/20250930/role/statement-document-and-entity-information" xlink:href="ycbd-20250930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cbdmd.com/20250930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>smlogo.jpg
<TEXT>
begin 644 smlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M2+R_+Z6+I>WKMRE+S/#M:N-2,L5AK&XS60* ORV#@]>_L:Z76?\ DAR_0?\
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, !V%%.%%>:>X?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-26-004777-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-26-004777-xbrl.zip
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M]\"OJ/=N,/J7]%/WF:Z;OAU$_(_\N:TII_UJ('^:?]7UJSH-G/X'4$L#!!0
M   ( )J>4UST&,]H]@0  'TO   5    >6-B9"TR,#(U,#DS,%]D968N>&UL
MS9I=<]HX%(;O=V;_@]=[;<S'IKMA0CL4D@Y3VF8"F>GNS8ZP#Z"I+#&2"?#O
M5[(-(<66%8*]NN'#?BT]KR1+1\>^^;"-B/,$7&!&>VZKT70=H $+,5WTW,>)
MUY\,1B/7$3&B(2*,0L^ES/WP_M=?;G[SO$] @:,80F>V<Z;+-0V!#UD$SO>/
M#V/'<UKM;J?9_^(\3@=.N]E^YS7;7KOI>>]O"*8_NNICA@0X$H**Y&_/7<;Q
MJNO[F\VFL9UQTF!\X;>;S8Z_5[N97)T-X\,%Q^(K/SUYD)X4O>DDVM;U];6?
MG#U(!<X3RD);_O<OXTFPA AYF*H6"12+P%V1'!RS ,5),Y9:< H5ZI^WEWGJ
MD-=J>YU68RM"5[:ZXZ1-AWC &8$'F#O9S\>'T6E;8!K[(8[\3.,C0B1R4L*2
MP[P0==^ BN!*U?W[T97Q;B6'@<#1BH#KOQTJ9!'"U(L@F@$_$R^WC(N#X@BH
MNE.\M+IS60N*N33N4I;'@_4,O$.-9Q)K2JJPC6&.UB1^>R._+*<0>$_[,ZJJ
M*YB%4=@(6"0K:U\UKSM-/Z&5LT ,LJ)8=F6P3G[(B=*3WSC>R5EBSGB43 HO
M7>QD>=Z^I 3WU045VI!V,<5*.I9_,[6"K<90R@';&.3DGTU1>Q3"@I/.$_O.
M%Q T%NS)#P$G#.I'TB9I]P'^MR^K#Q7"$$3 \>JX6H)F0'INF2RE(VIF9CQK
MIDO3W1&TT&$=GZ^09R [J,\!#5@(.3AYIZND67.NO&,1(/(W('Y+PZ$<6GED
M)=(**8?9&$_KO@>.67@GCXD<S%)M;9RJC<PH3Y0U,(Z>YP@Y <%(3B<Z4)V\
M7MHIFI&\\5DFK8$R'6W%MY!65P/?5%:AP3H^72'-;;)(]<.0@Q#9EQI3K1RT
M4FU=G&I>_L:G;).WM)4HZV*\9S(L(/_@5<':4BZNBW2BPI=O_)ZS)YQNS[2L
M!?+*:0?RIN"(C&3(M/T,NT+, EWU?.F2_  KQF-,%ZJ=<I<;$WGEM,,7NZ@3
MNF'.)NO_ILG?E%1(=1L!7\BN^<39)EX.6+1"M'C<:=65L]YA GP@[\P%X\6,
MN:K*V48T8%P.\R0,2*:/ 5O+FW2GG1J-KJJ!/0:.@A@_@8P/4';7:J!U\LII
M'V"!A9S]:/P51<5-FR^KG&ZR!$+*;J,\4?5D$2+DXUK(8$843]FYJLK9IF@[
M"E4N88[37.G7]7&^[H2R1%\A[Q@6B&2QPA;GM6.!HDHFIC:>2T:AL-F*)#JJ
MYX11GP<.XR'PGMN45R89M6Y F("PY\9\?;B]LF3=^1G3.6>1OAE9V1(NJZC1
MB"8#^NRE=*?(#(:.H:_6Q3OH941R5@_EAS5O[:GL()/KT3:^)4EZLN<*6$1'
MZY&QXZ,'&=J>.\U&L-?D VKNQKS''V^S=[II-[34MLY2>:1@:*UCJ;57Q)>&
M3O^PU*E11&#H\<I2CZ59*4-_[^SV5Y3/,G3WI]WNM*DE0XM_V6U1D^DS-'AM
MG<'BQV2F"_JE(N?+>=)O"DQ]V1>IE.:!3*W9&K%H-NFFUFR-6 PRC*86[0M5
MRM](,/5F:XBB?3!A:LZ^^,3L5013?[9&*":/:TP]VAJBF"2O33W:%Z64I9=-
M=^KVQ2H&;S*8FK,O8#%Z.<?4GGU!B^$;4J8&[0M=-*_T/9NZ\7_R)(O[H=Z7
M3X^K#_5NMSSR'U!+ P04    " ":GE-<H!;U"GD(  "]8   %0   'EC8F0M
M,C R-3 Y,S!?;&%B+GAM;,U<VV[;.!!]7V#_@>M]K>)+T ()DA:NTQ3!NDF0
M.$!W@T5!R[0C5-9X*3EQ_GY)ZA);)G6A1:HOK2./YHR.CN<B2CK[M%GZZ)G0
MT(/@O-,_ZG40"5R8><'BO/-P[PSO1U=7'11&.)AA'P)RW@F@\^GC[[^=_>$X
M7TE *([(#$U?T>1I'<P(O8 E0=\_WXV1@_J#T^/>\!MZF(S0H#?XX/0&SJ#G
M.!_/?"_X><K_F>*0(!9$$(H_SSM/4;0Z[79?7EZ.-E/J'P%== >]WG$WM>XD
MYOS;693ML&W\OAM_F9GNN7XY%K;]DY.3KO@V,PT]F2%SVN]^_S:^=Y_($CM>
MP!EQ>2RA=QJ*C6-P<21H+#T$I+3@?SFIF<,W.?V!<]P_VH2S#F,=H9@Z"CZY
M(W/$_W^XNU)BGG2Y13<@"WZ:QGA*?!:S</%$R5R^GT_ISFX\CA,>1_\#C^-/
MF;?H=<6T$7K+E4\ZW8,CO274@]F7H.&0Y6Z-Q'X?81J9B'[?<</Q3R#"?K.1
M[[ML.F:6PDC#,>^Y;#CF:]*P/O(.FXM7(]!H/\B*T?G<:LP^)8;<84%2%7A)
M"M]R3#818?4HR9J9;W!W#N+5G7(V!^][)\<]$2;?\N,"W/62!-$P8,DB\J+7
MJV .="GR>PHCPHP]5+*/P_)YE0":'/#.(=?TZ_C;;%8B:9]^2D)84S<NJ@R:
MEWT2. _WG8\I-F+@*$9'6_!GW;=H]X]E2%.>,75+8DLLNBZPBKJ*=H]K3F%9
MAV2HS5Q,! LB?TYR4N'QAVFC$1+W: '/W1GQNEP^_(/0D= 0^^-'BNH"70$5
MN"QS1V0$ZR"BKR.8D9R2:NY54T\5O9M652:DK1C>(1$% HJ22! /Q:K"ZI(/
MFHP:5=N("9YB_XKEO<U?Y%6I+X6=MJ)R_BQI*$%% A8QW)8$HV(3*E-D2!1#
ME@!G/ E>^G@A$8/T>PT1[/@Q??(S,,31K)]R.6=02H31W_T=67@ADU<07>.E
MNJS(S;1_];ON+/WHWT 11VWI)Z]@$JK2HZ6&.0ZG(MYUZ"PP7L62('X4IEO>
MM)%L^#%T75Z)O&!Q"[[G>B0<3GE0;I132?4=:NJEW+'QC)$AHQ0:/:;@_UI5
M4 V6H3YU556E&'JN(2+A!"Z]  >NAWW1R/!L%LI&GG)KG8%'[=6T2@0RF@#*
ML-$;N/UAIP*]4),S8_)0I)2:>S4K%UO)I5 V;:69NLR7*^FPA%.SJ1FQZCFD
M!"MF9-G7&DW,MAO3*N%8B(.U,]A*&8,R&AK(%S(M79 (>WXX(9MHC7U5SJB^
MIV[>*$>PD3L4J0,ED: DE';21XV3  <P:W0VNH E]O(7;55?:\]"L1M+,]!C
MC&:WIB@I@S(>#)W>,5E@/T8=;KQ\CUI@H7&2<YY,GV<!EUYS?^2(]L^UBCRH
MP(BU\39++Q,\]?.]0K&1YAB[Z\RT$-[JP:/ :V=:51 (U5@QFMV'LQFC+TS^
M&WL!Z2M3?8&M=MZ7^+14!!+(=^D'Q,'13=#6);$B=J$69887Y"+"!QGOF5S@
M"(_6E#+9%JS$%9D?L 0G<VMM[2T#1QP=)?"MK;<54@QU>;.1;_C0=$,G\*)N
M+)66A^::-X^V,XV88H$BCMUNEI&P*LLQ*JKL]R=?_EOS14!8KB 0UU/V.]9:
M^QS:O<A\&Y>3P$1OH&VTMO58EK4XY=19DU<N%.FH6\E64TY2G[9EU,XX7(U6
MJ,65C<IU"V&$_7^\5>$-2$7&A]:O':>V2U@,CAAZF[<8%=(K*V0%G-D0C<A]
M-_26PK,7W_5>>(85YH<*)^?6MG2R>]32 -H5CXIDF7P*F3.UB!/WYI=>Z&+_
M;X+IEV#&>G;I@DZ)J<[BCL*E\86>&!?%P(@C(P;-YZP6EGW*>(4Z9-EOFOFU
M@2OVL;13WC,\M#W.'%J\P">NWPC0ECOB?39E;;""(D/9)+V=.]9H_"#,)=LF
MN^Q?:JN13Y0^K=V%GV24&!H);.L)I9Q9J$67%;'PA%9-*GN6!PLE\VA;)J+P
M_ HBV>=4*A$%488%DCT.J&A,"NT.$,>./VO22%)':^U(,9M0F2*C$\^7):$+
M+UA\I? 2/?%Q'0?J!RD*K;7G':E72^-.BHUB<)2@MS3K%/,+-4DSG$TFS'U!
M$MG^^H#<P=V8UD(>K_CL-QUKI'CPMDJ.*X_68&+;.<-01H71-':_Q+[_>1VR
M)CV4-3X%5MII:\>;I70E,%$*VE*6DM,(%;DQJX,GXOME54QFI*^"+6>V1, A
M6ZY44@ZA&C'6KJR(QT=>^3V8GYGOGR6/ I58:UYC47@U+942^#H5KO$CT2AX
MDF>:6KEH5*81J$F7X19MZR4 >U>Y)/U+D?D!+9S,K;4I< N\O6N.E4F&NLS9
M$Y#LEM,JILT(Q\KMIW+1M' G:B5>U5IIZJY4G9I[X86N#^&:DJIUM\(>FK6W
MP+.M^EL0@DX-;O2(-.IP_/A?] L\-5I'/:!!H-$QY=+S"1TQWA9 U7.*U$I[
M4-GQ9FE2$9@H!6UI5)'3"!6YL;\,//)Q&-[,[R.NS0KW3:KL#UT4SOLU?B\!
MQT,P1P+QE[A94DFM;(6XF"]33X4!7W!\@H!<KY=30B7)1&6B\UQ8SI7Q!\-
MK %S0!0CVG\N3,4>5*'$[.NOXOM8[L@**!^-N1*ER[Y5S/5?AB5U:^N=6,G]
M1QDZBN';>C56,<50ES=KQ4=,#%E'I*@X<B/-,K/KS%8[OHNJTX$?&K=VTRV
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M<"TW0MKKTA _MV##[P\MKOT+*;#"[_H/ /L2_:,WJ^.=?P%02P,$%     @
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MRAQ5]AO69_1#WPMMBS0HG*RZIA?&6"85I62&2&/1"%MG9X ]H]@W7"FM>F1
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MIRI^12Y.1+_"BS/9E/F'*X9C!"*Z0I% D8&7BFJZ!P$/X(;&0>W@X&<U%Y*
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MN)3G!AH2X#OWV2$TN-" X<K@5Q4^%!;K*8Q5A,Z4.+A9>U83^5#.!$/(W/@
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M>/+X38=<=O/>8Y[1>:]YYHK<'"#7\XOCWUI7\.])J]WYTCF]6@8]Y8$*0H$
MKSTQ6889OL0N$//!U8MHYL^IQP/)+#7V!VOV<%::IF*N(>>V.$56U<+V#".1
M^6$*O^=3)7( PK<S/]T!TE7?P93*-J],S7729 AR^'\$\YM7=V ?%BE*LM%E
M(RWLG^JU>MW(PI:M_\B7H&WP0N.+)^?<CWS2.XZ"+9]_H.)9G7V>952*/HBK
M7>CI@1<"H28>@TFS"\Y$AE=&3'D;#A57-W4?DUX-+>+<B YNZ$"9.BD#Z4 @
M9A-S8B0&5RO,"D/%,5^'FW:LCGSNA=(DQ>ZG,=FG0:852;/(*@Y6G>7\MZS-
M8T(NYBSUR'5'/:QE\]I0ZKBD<LX.R"[FG/3]D(P+?+31I_B67C(SH\K;G^9^
M$.P2-ZC  "M&)?+VB_H"5KCK!8YV^$@^*-O.LE(;PPA]1T97>9\,:J#6UGE\
M_;).KG.2:;Q8FKBO3LN.;M.RYS']'].KYS[YR1GR8\1?YIXUI]>+D"EE!C_M
M?:2:7]5_)H;J!$$Z,A([Q\Z4:$!VFR1G?@4_FV$*.G%&<F(TG:7WJ:UR&$II
M9<Y&VC(*ASU\9_BOSL]0Z6MP'HLOM(T58&N^*[3O@Y_ZF7NK4]OZ4PHUM)TH
M! 4/\Q(F>#:'7M=+.(,7%DCEO6</EH\BWBN)E!6&WTAAN-N4LV&J (%&K#<R
MMI!1IP%-Q.")Q,'H-QU<X*P='?AQRWJ*D#+JIKC)HQ1;G/JZ3Q&QG:Y()D+.
MK-AFJ>!>J2+(54[$8^9$[*UR(IY)3L1C1TOPN,,Y5Y%8@W>8R8OPD?.K',5#
M8S"M4]V=?N)QI"T=%XPR>[[%"@KS-XJ/>_ ?T&-F.J^70*Z0@@4;$,C^ X3D
MF3F<*\U"91&K?FB%0BC*4 MDA+C<55S)RTC--2ZNG"]%&X+0N@ZYQ36YCZF;
M=<BZ$[X<?@0="WMIC:GKE$R!U%R_(),^J*SW=F9OQU8+\^=E=VAC?T'=3RCW
MD;W+TD$^UN4#J#.3#H>]AX$6?#%@2X:&*AONR-2W^4MBY/[>0@0%K1^D2P#"
MD?)TPTD ;QUZ8\.JD-I))H;)P\(6'JF-V?T@MN )E$ 84@T$* 0[9F^R6RCF
M;AT'2,YFRG+!^*F6\!F2'Q[JD!H]<1P(O?^8NA@XF:7 -L*UR-D(6;J+OI44
M_Z!T7BHE!%8;;@2S.U=MY(HNG ).:X!-$F*4/SKH')F2?E/@%AI*728*PX)A
M(W$%4A_!^!BW,(WX0EVO@;BWE-,L+7%ETM#.&$4%M*(*I= @5$V]M$:& 5H\
MN<Q_2R,BQ<JJ!38N[^2[HP(TZ_PL[7$ZV^*4&Z/.-'*<0U_P?,R25YW=R9=I
M];T;BB#?ZEYA<X_RW@4N+=E\?#%&41-K)-!)ZL4CE5E$8?*,LW)*C5Q6F=',
M:]/G7ETRH=^@PHK GFY[.=-CE;=B=@4]5[;V&H77RM%:L+5Q.;!=O;@1HW%B
MT%[69HQM8UX7N+K,](UK3%NM N1@4T$.)E1>AJ1V)R>TP79>A1'[-9#I!LK[
MD'>OJ,/V*45*SOPR"S=G](PVG>A3T4TZYS4ZG=<'ZXX=/)&GRNP#?$T3[&Z%
M^AW>J5_F GV9S.K-A=MC2L4HZUG)#Z27%I)!R!:7MJ?^3D++:J6EHF5EY0[3
MGKX*4C]?))$U9V+K5L&1\$9=$J.5-$MU"X:'X*<&Y[@0]Z<V0+'4*3 /,XBI
M9IN\R',;XLGL."]"%1+8-R5Q>'0" LE0]1ZC!DG"PG=ZS(\31'AVI'8RSXM0
MVE<1&&\<VC,)P//[,%<M(2HQN Y](6:6868V.7FD3KC1!.R%4^I5!?LP\<DK
M&F9+W=;JP8M"PI[.K:72X3135)Y[F2M%J3B]S%O(Q="N& 59/97,[66:FEH"
M@U&8<CUEI6#.H^EQF8*=*SYGKF:$H5%\4P)Z&/A<)*2S>)4#SLDO#<,/9R#9
M>%9L?A!8ST(^!6F)31:M%^'H/4Z.*GUN/H-':\TC3#O'@V&&8%X+?2*\Q"!$
MGC$+!?"]Q*NX48YM(96 IB@;SZ)6!T3GAD+6PR--1$D!45UO&T;5C'Z\R$=1
M$X@$F&.Y,GX56$,@"LQMKYB ^GWN1&R*HXZI!H"-9Z)!&=B/K<Z-M*0;]5JS
M2<_%O[9MY3F@Y'=;!_H+YF0>/2.#SBA#P%#NFVK\ MW<N-0"T#,H:;LUPI).
M/#HOC^8IE>@T!)D#2[RIA",PC\_"'9C]#5_2I"M#7"5:"3G6E' ?4J]GCWR"
M'I:7<@40%?8@RD7@#+ TGZ*B213Z/M.@Z@HG@@&6BGKDY\0Z7W0C1824Q)]L
M>MQZ:T.%[&/<%DK84:4G&.(AUHUA%B1X(]YS 1HN'(:Z/+<RGFQ=?CY3[$JW
MI6_UDHW2W C,)OVP80UY^TT&9:MZX*+KSX,C%-.HR9[_L&%;(D:0*R\>HBBD
MVA6>"4@USU1^]#.*B:JP0JE.LZ6I5C/<EW<J*PC4#,A3L7&Y 3?/X%R@QBVK
M.Y-H*<0UF?-S+H;VWO8+52*9*1=K/W,&8@"'(AR!ND(%9*&L#C>2NTF_FO=,
M'AD&&3'?0;BHMR?#,!VP57"K94M#J7YZ. FRN:M2;[O@SLT?EDG )_R6(6M-
M$6LY8?M]&.981!AT,VK')>B<B?!9D=]#I?^4AD@16$D6S_P<5*3U?@4;_NRC
M=7YQUNYTCEX-!-I500TQRAINZR8J,WH4[ADE)F&Z*B> 8BX;'G[\%RBWW!Y6
M%;?L<)&-[8)I23*I+(&H/G1S3'X\OW[VS(E0[W*SVMV[):HJ!J$K(^^8M;K*
M'7C$W(']5>[ ,\D=>!#&?M2!'?UR?-JZ.CX[119_]O%CY^+X]!-6<;0[KX71
M4XIS"7<LUM$KX"&*'*W'&RS[RVY$_D]819DST9:EOIA-38 (4D:0VXD>*JX=
MCIE)1!R% H8F3J(<KC["S@Q =2/KFB]YF5K'E];%KYTKZ_CTX]G%%Z+0UT*/
M=\2<,ZJ"8^IDJDQ7[/&9ZT/^>JH6SH*RUG"X1" ,$@D>BJ4CCF\@B,^:XF7+
M/0'[_Z=Z;;^I*L"SVA"K&"+6KP;-:NA(>(\;@MJ D]S '@0Y^P?KA#&@QNYM
ML/K37+S0N&YFK$ D8$ Z#.[J2*30[%9^KGX".]NY2U[!7!J&$I2DD*K#@%X3
M AM5"&APW1 !<M"IGH#YFEB!PUIM-PJ_R9@27=%5N&=H@0:"P_JY$<XL M=S
M:_>K'.[,:+/A2):J1I1$B+&H7TP^(N^ELDNLO;SLG)R@]+[\W+KH?#X[.>J\
M'L#J.=8:A5W".*8*"6DME5IBU8%1"=S'X=7;K#\&2<+P9Q@IFI1%BAJ+IO)5
M&3,O<PS=,2.!41$BY7+/RN8K+$5ZN3^=24 J&GE%'U:6KZ9&=$OTQ3-04L>H
M7B75*X)(*&A(FP-'P[)J)VOH8T6_EXK 58=XY)Y716 6C4!7NZT9.\HEZM'
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M0-=A_X\F?_;P8,$?6ZQCU=3^=I@0^<QYS@A6U)0%HM_N8!DK&R>J1@]V-QC
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MK7X;KWF9MOI<;7YEJS^2K5ZB8<VQU>?NF<Y7A ,%>C]F#,"A&X]A-;P;N-7
M,+^9FG&<J^^7X PB1AH''91%=7?6^-5A7V1V\/AU;T.FZ'--AR/SLBO"\:8M
MP)K[N@=/$+@9I(WSQ0B3EE@C@3!;7CQ2O4VH%C'CQ1@<UUUJ=-D$?NC+]C&L
M*!AT>YN),6->\$[,+J'G4J%))$;AM0DE920/X')@IC>WKC*H-6MIP]%^7A>X
MNLPH@1$4$J:+Y69(G',KNUY?8NGO,L_Y%?J0*HE%X8V6Y8.;?4_GYYJ3IJ#3
MRU5G)B<8:+/WIV:]UMACV]_>WD4'D 0&'WORX+F$34=7_S,-!',?N*$%S_/Q
MTQL^=KJDF21#V;@ILU]U1] V5E&2M667*(:6B#6VQ)O-7RL@)&A8V\P8&S3\
M+R#-MNGS]@L]-"?</V4I#LUCI6$7,O5!*2#'E=2(3O^X[&!&'U"Y8[8RB*>C
M;NBKQ+T_VA^.:C(U[\6M&U'&%4**]DD $C#_ZZ /XD!JYMSMIZQ?.)+-;RQ8
MU3K9ULE)V[8:;ZP3I^],47G@O@:V]7L8ND!0\-?I'U:CL7OPYH5RDR-FRBF[
MN=NZ^99UKA!\0X39F87B+@ 9GF15H:^%\)X(J[P*JGPF@I#AF^;R8TT\<]WK
M\!9 <Q/__1X!S:5J_,2(YJOLK\;V*OOKF61_/0APT_D%XDE>'7=>.U@>,,HQ
M^E'$G>'RFE5NQT7A\L8(EX=FX.)0D,\/(^_Q2/JD\ZEU8@%AMSN=H^/33Z^=
MLKGU&- WMAM&\_&N!+[]HP1^S@3^G5"G*UJ?@[MW?-%I7YU=7-I6Y]^=]M>K
MX]\ZUMG'C\?M#GZ'T,'MLXOSLXO65<?Z=/9;YP+QA3O+<"(>V>M6<C@,#5OV
MQ+L615U;GA%K@/[G@*+?MY^>LK-"20:>"OB8H00\ )<8>4#X^,9.JT0X-+<K
M#D[F190@':O#4GU8LA/2/OMRWCF])!CM9WT6O@\YNT)09(<@WPE]+KTCQ[]_
M>M^[A=Y7Y'X[N<.2?;TXOOK#.OO]%*3!Y^-S@F8%;;]U?&I]Z)QV0$P@U#S_
M3L(B ZV7L/,G(#B.&,?U\]G)4><"+KD"(W IE*JG%R%X;'264Y;D@#'Q8O(#
M"108I,.-SY]"C&PW5F+DQ\^5.D%T.+ / YRLR]QQN;IH@7!ITX_T@U+3K./3
MHPY(GJ/.2@F3M*1213@A*0SP_"BL$9\.AMDN339?9KV-W)*8J"&>2"W;;J[.
MTWW9ZTLD5A[+5B<,POE]QF0#)6H!1!G2Y%BGC%QNW8IT\LFY]@9.8)TX$]LZ
MI\!6>^A$?IA@_F$^R_!EDE#GW^C$?%7$@VFNL*.<*9;UNM'LBQ-#NNZ7(QLA
M;6H:8M[,U-:X4E/A1-BM%-TM&:Z.3*_8I7OACQW;;(B; NTRGVT#F0*S^R"^
M.<#)K).3<]O@S8G,Z2*"EN$BI]=#= E*2?&B$;E[BNE[7H1X$>A9HE 19BB/
MQS!.2MP,S+DMXI R9UHY44YXJQ8CC#I1LRYEAN@M.S ?4E]"6+#L\\BU0 =;
MHD?@%!2F#:>%4EHDQM=\T")!_B%>:>0,(F<\Q+G>MMERE<RL48PE>D$JR-MF
M<<00O@.9'-C6 $M_5**%+#IC9D4CQ'V3\3Z!*3N8XY_M*L$#(X4\<@K;*J+7
MV%E%]%YS1._WSYV+CO7'V5>KW3K%AG)@U9_!-\>G'\\NOBR-R^N1^@[W&4<0
MQ8*=U='9!J C<UI*/\_I_R;HHV<HYJ:NSRB0U5+'MOZE2_>*J8WP^[]X''.2
M'\V*@%QOU#BK;]43*!\O)V;+E:#!@R3LIU'@Q4-=_0%FBYE#<BD3I!O;#)=D
M-7;7W0VEIYK-E4G&&4#YD6!X-= _!X3+B5)H(D *)4*FR0.;&.@5U**[X\,[
MHS  Y>#(21Q0:G$FA&W?DEW]>(87(@%I=HV2=AIC>&J]<_2I=:%*,&$F"%[/
M=1@.VE28L8W=R3W5,%.7:12VGF5_MG(9*52M+2@V3L25)(CWJCI8TU(+/2&J
M7\F9B'#-,$G&\=NMK<ED4@/%OS8(KVO6'V'* **]'I93X.7E^?!48G=+BQU;
M=<@UEUENQ5R1_/Q8X<+L@*I3,G)5Q&@0J5V@842/'4O$6@*#ANWCX@4J\(Q#
MU$MSA9YF'V+ND#"9H0:B$/,<#H&0C<.8/SAVCEI SQNYM5XXRKKT8*%#M:))
M529%,L$WF:1<?",2O-%?"M^ "J^'66Q>(@%;F="8+^2[8;^$QJYW:-9K+"RW
MU5+K4HU@)[>NQ(%DU.81U#%ZG(CUP"(#V=FRS-YLW="*C01"V'QZ3.H+NC@_
M/C>$)9';25XGU<PY)^3DZ*3AH7/YYK3N)BNAUV/_&HY>]PHC1 GI28OG3#SC
M?[J;V3P.6/%\7<QLSL?I(FQWFF$ESW:^, 1_<<F0:] "XWH919.X@K*F"84S
M96;"V8=-TV5(NEV'&_921IVE?$MIRM$,;FFF%@@4!D"EV,*"X"ZHMYPN=_0(
ME!H8,V=YZ'1/JN<5$OY[RBQ&6]8(V1\),.=FN[RA3J'7MD^8J+)0+^]<X =E
M;Y3PX'?;K;SZ4*4<+"*UEI^?5"CLQZ<J14-U3Y0!!D-CMS[\85UT/H)FOR2!
M@\=R<ST;?>Z]=VBH<MC=,%-(':PLCI']P &300!#7.?.H/3USW!D]'C),(%B
M):KHTM3M/>TS&@DGR*[ \AA5A66TI,P9"B$)?#48\K/A%X@FH-\XCL0UEC;[
MTU(&?C4SZDJE)-;ZA"S5%U7*A&YK5&K7H(M+_)G"Z)1>E=L:<IT[:1+B;;QU
MZ9B 6HD1I9A"+US![S2>CW,I*-;97.("VRP++.DEDQ5+7$E*?C'L5:9_GAD_
M+12\+S>-$NLL9O/,QG]Z^,_.?$N-&D0H6<-8)#H"1<G_&'.01;F%< 3'[+I*
M#\BOR[I23AR3-,/\R<+R<][GS(,LE5^A6BXE<OK2DQBYY!.E93#TF1G !UEP
M0(7&\WVM&V\?/ FGP#L3$FOL5?MEK;YFH;=JC.7.P4!_CL=.3WTN<U?F(JGU
M\0V\Y*]_^>M?_O(^Z8;N]/!]HAU[!$0%1*ZLKR0<T\5XK5MXMF2R:KB)6W%=
MXPU=1S]^G[E87,:["P<<YL'>_L$[8W%Q/-6CQA/_]*.^)1[Q$1@R_/S'O)!$
M183YO6,-@;Q_64/+,.]&V/)N_@_.X2];K:@W]*Y%O"5<$&M;P/2<K7J]WMC;
MV3FH;].?.]O[^SL'S=WZ]IN=[=VM*=B6^-+ZP7;]/XWZM]HP&6F:W(3G;\*$
M4<5]*]4YF.-,[N[[+><PE[]KSGNK]2@3VH,_=W>:,Q-R%IG1/YV ^YY)V 6<
MT S-P;\1'D/XET_A%IWUASOT>;__W_],P^1=@83YR]N<-97<XSY?4,EQ[G$:
MB[&N>WTA,:';V,X]OA'=RT47<LZ#G'4&@D>$KF0C^DQN-^9RD2Q/99])_5V!
MO/]RBW"Y5Z)\D33S'.7FRYD^(0C(\$I4@BVQGH57WJ!PVI '!:Z9\],\654F
MH\HE[MZV(: :C6;]/V\6$KAWZ#U^&E[+#DF[2C93PW$6T?<TC9V#?7,:;QYR
M&F]FIR%)^U[FLM_8W<OFTJP_P%PT:YZ=2M8&_OZ5H6;C0$ULK]YH;-__Q)36
MU-A16E-A8J:=:)J&F1G(-?)<5%FK-]&&I _[M7J#,'/4L66T&NE0-*'L9+6Z
M?KB=X7L%PJ/W\RD.R#Z]Q5Q\AR]Z<L5O9>T]$VL/A<T=\HD7$B??==JWWVPW
MLM/>K!_\!X;5V%G(^)E)7<8#7+O#(7C9+FGVGL$/.I1#R+@&.Y/>:.G'@A_S
MZ1WY[ [$XX-+=" (&0]&_29.G/%%&X&B->LDLK%SJKRM0#R,<&ZD'XJPG&/1
M(_0.='_>%BQF!Y_RY#WSF,MBVZKBCF&7'.Q9Q!\6.!:&5W-N?@MLBAF>MQ?.
M#X"W3$V_Z*RM-B]S)O?VV502/P[5O$@Z9I.!?8_3+@:-*;W(FD08/PX(IU;$
MB24%IFJ3J; N$ZO9 'G\._=<'X8IK- '_]JMV=9EBD&95C[_O UJ6W-_V[9:
M^'36'*YJL)L!4/.O(H"C,N6# /\E!$A^?1?!21GGIO#^]?WZS@:V.=_<KN_5
M\U"<Y.]7>)<P=.I?S#@YQ62J8HF6C==/A@0,GT^H<84/S#?"<X=H_N.I"OE2
M@V9?><R5A4&GT83:F7O8A/FR'/>8$Q3NI@D=9#VRC%Z,IU$^,2TJ0@CGMY?2
M@P+, 8Z-"#3]A$O1Y7BVDX$+ZPV@] 'TVG=!+U\E]SYJ<N_N*KEW^9)[\=6Y
ML3VAN%R]XP[5CW-<6S]>@B_/N()9NCSOM*^^+D6-TO*K;16I,D:)RVH=?V =
MS[)0/X^@J="I<5GEH+J'Y0C#JY7_@97_#_^?]9__*.OZ=2SFZAU/]HZ5UCQ'
M;UQISGHA%M5BGU]Y2!7V9>OBRCH^7@86_$")Q5G^\.G9E771^=?7XXO.D75\
M:EU][EC+I90^#,@UQ8\:VS7KC'Q9G1O$M6*=YEBU,T/GVI'1)&LI=,O'2K#.
MVAYQ](I:_G 9/I<XQ#)G7ZBE4UT).4N5W*5!( L&M1/*,Q?7[$!6DEW:%=SP
M2(,$H!><8H$UJY5YUYP1%I=CO\!P$E#A 'H@L?0AUEVV5#8,E]$8GK.^$/%C
MNJKN' J4G+OO!5=XJY8%_ @4'[XSCH&CJK\*<FB^3+Q##L?WQQ^[89*$H_O+
M'BD1G]&@N]ZL8X1Y&^/GN[L;LQ'/>WN]7-\WNS_/CRW^R#MN]RFL'982\P)1
MT<;/CYLY=8^OF]5'UPY_FO?NYL]YQ8+4UH<=3[.Y5VLTGW!!\CNR0,;>8QW0
MW5TZFP]]0)_T4)Y''B.=*+FX.I!/?B#M771@K<[C$PG,)SV/+0-12HB\RKHZ
MFD]]-'?9M[PZFJ]15)Y0 X+5J5R^4UE?'<O7*S&_>#$Z(9Q A.FK.XS2-;/)
M! 67C6\L0G.D_:_;%O[_C:4[LPL/N_&H$E<ZMLQA/:_S_AK$\%68./YK/^?;
M<&#<,$7G[+,ZZ-7CWF_:^X_JB9*'G9S#]+_F74[[RRX9,&)..[69YJEAWSI2
M/8=(%3Z3S89>3<1)0Y?L[FZ^V=RMZZ1V_OQ&Q7KRH.76)Q$(S&*^3)PD380"
M.Z-D[ Q)/PEUH]*IA95A)2U4;4N,QGXX16,DE$V#8UEX)O/=X6LX=4-X>$RO
M0Z!E^"X(@\WL"T2P&E$I0*$W:LWZFG6A+EQN%P8\<J:RD$-!^W 8B_&[LKDX
M>B9Z(MD\]#34VIEOF Q#K"6QJ>,JEKQA<GHDG$0$&G5GY+C_?WO7VMRVD6R_
MYU=,>6LWTBXE$@0?HIVX2D]'L6RK).5FO]T:$D,1,4@P "B9]]??[IX!, !!
M2J3X$ 1DM\H210"#F>XSW3W=IVEDR+Y#K-"8Y!U_J\*0QIN2Q6(J,$MUE9-M
M&0 K)C9QG<5=YK#R3M!\]NP'VZFPGF<CXPS\Q"WX09UF/ @YKM$#'N;=JT^Z
MHL>QK$"]41\>(Y/JJ8)!9O-3C4SFS*C9\+0IFIF9<#8P+YZXQ[T'*@L(]#SX
MB.M:G])Y3\U<#SZ218^)A@_$OB:\L6?[0M$,J;6&^<>:#<6Z)UEYN@Y-BY3O
M,59TP/+\-;'N):^:+X+ 41QKL%#<"4"F^O9(Z 7,Q#770[*<@/]@V$2 ^@B0
MZ'F"J@7DPL=O(8LC H9DX_NJ'X<J81'Q63 \ JN;K*QC8*Y)@SX8C-/Y0@8$
M]BNJDB&[S[#JC7SO >90?2A1_\@REN>L^YZ]C\.R)CV\?& /X;FHL>S>=2T0
M*QAF!;X$W]+J<[K"L<4#]AWD^W&)EY1TF+_O5-'!<-7HR5@^TN-XDAMHK& )
M):0VT?1Q%Z7*QM57XI7^+HQ^K[L?UG/)XA(I01SG>R!IL_"%4%8=&'5 ]\=:
M$'<\=GVIUJG;1K5"B>=+7BUX?7A_-3Y\2D1GJ!0VH=0#CK6SNBQ(324HH7E+
MC!&'!JO&'_L3YY#]J1 AUA^XG\^&(M8ZFVC= #A'%O<LF7HJ;Q4>[0?3<1;N
M:NT#J"Y%ENU(FBM9=D/S[ZJ[:EL#I^Q6K(T1J;]0V1Q,@,2Z4&[5."@Y=N Z
M%M+$95%6*5V0.UOSD!VGL5]5XLVBO-8L?&;'>4K1NE.)IW)&T4S-$C-[%+$'
MB_BQA*@68@L"O"TI&6>$2=U_X2BB^_/%=U?=!;K<)W7"HBF9"](3]@,1@R%9
M';7F5;#/G1":"E&9> F"96$;!<)_J;&^P+X/BL&.$VE>U-\HK14Q<YO4BOF2
M50DE5KZX%-OV<@:9O\@BHWT1ZR<3GU(577\Y<RWL/8]")'M9)!*4](T/O"=O
M)&):/MITPLK<[/U)[Y3;)>LT4%J%;9G$@,,6,JM2L$?"?DYFTB14.=N3LRR9
MHG'7DM@!G^-V\B#3G\+"3+6)V*ET)AQH^**VG(;9[=>-FF\0>L<W5RR)GHC8
MP .06KF-5=CW$:92H<$;[GD*)Y6))0W$'FPS'M'KH=+W'1N!/=SH$CN*GS$Q
MDB._.X5-P(\*,_NJ>Y<NJ@II8*=PJ/I4UE@G:(WA'G2I')Y/YBV:;F*N599I
M"U(9"<G3C+DG_[3L/<-UFC'V*F15J[: %?:7"S/%'N#R":Y(X$U\C2(XM@IE
M83@^GKZBC,K8;(ZVB'D6&^PVM!V!/&*W@T>A[,I(%Y&J($O=E(9I+Y>YN86E
MP0D<F762U#:^U<R[U^+;U@F4Y,^MY\(HF4!(B9P4(F7X$L!B@-21&:QVHI%<
MJ%L1,V8EA;3Q5HS_ETM.*H1&&%4JPR_($ !PA)33H(F5<(<>"L^6<J'=7ED9
MEN@C'(5VHX:J5$^-9D#"9$\\GH?M"J;H.=-KP@V(N2"&H[DO79GS5E3UCB(O
M"?_'8R=$&2+^#<O\)UYP0'$V\F"2<&2'2 9?BBU)7_-#LQX,9@RX%8B6"9=I
M2H3;@2.M\TQ?AT?H2-Y42IH:NC1MGUV_K"&YO#PPR@J2UU=[O3.XOT#?&#?7
MI*/W?(M9*KL"E)G (#(^]P;HCLN^P9("'9#!GWBT#R>,4:+4@E6P+>2;14R/
M8UNK1P]#.SN,3NIF:&1Z$HM(%)7SX[@?F0/!K.NI<S>KMG+_%T-]:MI.)CZB
MKL].M5L<RW!5O+7) <A-).R)$LZ?)0.Y,IX0V3Q1,SS<#I3U$WX6NQ5C&$1O
MJO8P9!;!2&?W+Q4NBZ<%+%0^$[55W2;0U J?D&A?*YLK6'P(\^]+#IBNZ+E@
MG5.\P9F&L3^Y:5#HSZ>&(O[$B9I.C,0]?(F:<&#G">%YM,[PS*'M^Y*0:!A;
MT/'#76U8\()(1B.Y/J(>$5%42WDOA;#BTIU44O+H8(_58VF.L%;8%.A8LT^2
MW7U)-GS-I\)P4B1?>KA)-2X9B0#9MT*QP ^['I+8R+M;DV":=$S2?B?YBUIP
M7KM%]@T*L:R7(]_M<W*J<"UBE84Y42<027.LCVJD UXXS7$$Y38N84)$@LDU
M.J89!JUC*<(&"EF^EN;(4NL85Y(= 6[H;/_D$[N>H.Z<E90%'C;3D1U9K0>;
MXK^PH43&N3L&IS$NN]+&C%@4-0@X19 @O*A(--5G:'9V[#@(HSJZ*JB4#4$]
M>;Z@AI":)VK+(;L8>0+?#/T;@=QE/8%!P4+(XRULO>2DX 212 7\.X6<,(Z-
MJDQ]8?VQ.Y+1=7FHW Y;T+ZY.=).SIN'[$:@G<YNN0+5/T9:>6 L3Z_AV'SE
MMA&Z81M.2(;I&Y;BA?N3ZO\D*<C 0M<**<.6* 0)ONM$&NC@,1%V/@;EML..
M)5H_^W[\K;[L24!MDC'4@Z*8*#Z;AW]XQKR ZHPBU-<8J[Z\K$AI;H8/3O=.
M6= V 7D1,ZG,9]H05#)OO9A,?>[=9XC2HY8TZ0<DV:839-,1X><WV IPJ"VM
MO7::/I?M^0 1JEE0TJ: 63M5IN>E1OG8Q7=*=A':?],XT3J$_4OK*G81]>"^
MC7CR0L;55P$5V]A8\- :-Q?9_D<R@&(>TH\PDC<&NY+9PZ&P;)@DXJ,$U;%"
MEC\?'L4Q/"V_* E)98";.AFA],7=X4BBN9_LW#2'LC!4A=L#(Z1E3@XPC1^J
M0;H.(V]/GK.6L+L/;D=62_E4X[PH7ACFRZ1[9"%_)C:GE[DNZ(VK +.ETE]D
M+;V*YJO-(K.5O3KT1N)'/Z2I?7N+H8%+6R5RA6994?#C+K1'$0B$%2DS"!^N
M.I(^J&D1_L)V6F]E0O:,?7;G$M15P'OV0O98U7 ERG2@]FFD*#X/%50R6T0)
M=JX?' CX6H_XP:->WBQLSYL-G,6899MF.<Q\4^=((8]MA%H8; Q[D]=@J]LS
M]S,\6[!&=T[BM9U)D[,&VR,VI\R@$\9YQ.Q)>:+[(+,G5" CXIYFL4Q28\2(
MS3AS&]]36\$0>8,]Z:?-EVS$#+>_+W6DH@6I'3U/B=_?8^M-I(L&NQG<7HIG
MLCY #=XKP.PK&:=0%R3:>D:)7PLIDP]A3PW0KJ=@<&CN:)$52>3>PS,["HM;
M0OT,MWUPG8E,]]7<+=)XS!-41X4!%E@P"_E9//; G<F\"QZCEMJ8YZ$B-F&4
MF?L:%8[,O,216>+!5I&I,-<'^TEB"IU]/\"^3^&ZA:PX>&KPPQY.AG%G1X_F
M4 6HE-3$<1J<4KR)WLPZY0T]&3U*A*YNL-5!H]Y @\;N5S)6FPX'Z!Z^-LUX
M[[%G]X0F#2-7=G4F#GP.+A(", E?4C+"=XX>$K^]O.6,N"@?ZY0[O8D3>5@W
MNA!=B+@O*^6MJ4MCD<^6N;B!R Y1HCS(31_DULN#W/(@5]]%9XV/J*.ZOM.D
M\^5ILW7X2)[C:!QG".U:I^2P\?)3I/XJBRQZMD*VC+Y&BV_T(?(,*PP</-CW
M/=4B!!-'[ST^'O@,[%HPNBKR7UMN-/)G_(6212V7W@339Z9A/DRR7;8RRV2>
MH)H_V?ADODU ![W8AEH;C)WJ?!!V4M#V'YB<N%.4FOQG[$?J6%ES8S):*3/#
MQ/M'O^D]E+5G)-HIR^.>ACJ^]\33;1ZR%RNL1$GVC9F_&<_;8&7)@!Z*F6L)
M%<(VKH-.TT%8U"%SXF%]!"FK2N<*?;GX1'9^=)L.4&6BP3S)]@<8D.\*K=MU
M%W/Y1O"F<U1>;UZ6HD4,K<5 QL'B+NAZHVX:D'815X52E.6;/1ZIQ?!U3*5W
M1R!JE#48WE29[,40$E/Y3T.$.S*L$^L$6CP4?$1'4 L03>6P/T5K*0U\>!A&
M[B<C.J )D[+GMV,OQD(TGJFM3VMJ6,$8YO]XQ8B?'.^S<VIUE-XO%F^ V@Z"
MRI"-&$]O*7@&H+Y (0091Z;M*AX/NK;JON$=*1= ,QL6V31/N%)O9B5/9E<R
M96@M- 1@XZM@#>%><U]5$^ZU]_4S&CYO#<GN @53V87RGF;M)+%)D;6KM@H,
M;&8, \PGOA^9EP\V_H,C^;&?I=W25 WC,9GF)8CPK1[URP[Y/2&\SQ<U39BQ
M\,7&7$9-MFG+S3#/,/7;]OR 32CID*)KT6Y!.8SJY?4@F[R"TG^X-"HQ>IR*
M&X6I/.&\QT5=,Q&_0W:<S"./5E%"JY;;*)<@>E5D;*:*$BL,;U,%D+(J0[O"
MDG5G$GVQHQBZ%C(;GN9F@06T5)1Q@5VT>.VBD@/I[^@ZY$BJZ.V:4>P7^^.U
M6H]?JC:V7;8_*J=,_DX/P@KHZ!U(K\@+F.\H:F_V?,L?+XQO'G8"3'HN%/FD
M]USDT$0-X]8[/IECBTEZ+AI<X18>5IC2<LB:X*2^C#W;]2)'.2EI*)\HS<*B
ML.[0M<*Z0TUJ* "+M<AJ=I9[N4>^].R/ILEVC*DC^?FO4PQ[L*G;@SI4K>RZ
MP::IY3K%YE"4N<-EUI%*W,F.$M#FXR4#!(FHP!Z@"Z7 >U'941</#E-#F%>W
MM\Q@YHTA#@6L&)$H_=C<J4MKGVD9SAFYS,NE,C\SA9E64D]=#M.99Y0L(<%$
M+C&@/#QIJLBT8U7?FTQP3MTFJE34<YU73G7.+L3;:&XS+),T+!_B!M(8JK>'
MF371X4!42G:\A'NR9)A.P\9\&@=6$]-%N5HSM>(PZ]PF0,@H#9(L/^DES5A1
M-0%QK6BZ#G0^-] ^S3%,HQ=H!43/'<J<CB,+(B\S8B3-C+"J=D9Z,+4M9/N0
M9XH!RFHD?))SQPI[Y$;CHT0ZR<I#?96E%2,K2'%2QLADX>$>S_Z"L?J6K4AE
MX!E4@2XIFV3Y5*9L=I'8ZL422CV2D5?'!2-48T?I$]T+<71HE&5R(.@=E+U^
MMWQ0:98'E84XJ)S3P.O\O[]=GES>L<NO9^?_S7\"8M9;W@WT%E1Q;_HX>RXC
M(9]@3J4@+\Z=TY..%Z+7^M_L9>V@5BLTT;5\IFU3FALTQ;6KJ';E+1J'[<5-
MCU:8KQGIEDM(<MWUJO)AW8]?W9@-<PY1[:*1FXVU#_P9BJKRV,\H,$<$CB]Z
MAQV\ FK)2\;<.'RB3=9F1BT]ZA@;M_OX,X"9%TW:#F5U5W/V0OUN[E+.P"'9
MU;1=1+DONQK!;^!*X3:<M7H:E?L3BQFXXVWM,<:AL824Q0/;[!:277;"V< 3
M?;""@V#\OEI]?'P\!(?V$#RTZK'7&]@/PJ\*ZYY[58L'O&JT&HU.S:R"66XT
MS':[T:F;-:-NMEI5\>-_FX;1;AX=#H)A9$@<P-T.8! 8-7^OC"=\+M@<HX0)
M;XF>JC-\+^-#(/C@/[S[^$=XXH.*<(Q$?C)[R:+HHCPR.P;OUF%FC4H83>3Q
M#1[18296M0I2(QR2 _H%DW39)_ RQNSJZO27*@X#A(HO PM#V[(<L:LM\^C@
M\ZICW<%6V:R:U;JY\H"W/=Q5-5=M#G/;3+P>;*H7 YM:S4:GV3".:H;9-&M5
M1SQT_U?\J(,SMEYP^B*\>^'%L*10*2H*-Q&1C".*>>(!]] %$+L2#\)A)QY\
MXDMPJK#CWM^G;@5!J:*X(.%'NN84:V)/B%#H#"]TQQ+_2OS:!B#4 <",H]P
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M0J0,=S'=?X_.^.KUT(W4L H3G"88JA=:=/V; SZA< *?G<LA^GF-J><LQ-7
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M,C,P-#DN:'1M4$L! A0#%     @ FIY37":Y[)-Q"P    P   H
M     ( !N0,  '-M;&]G;RYJ<&=02P$"% ,4    " ":GE-<K&2!7%8$   ]
M%0  $0              @ %2#P  >6-B9"TR,#(U,#DS,"YX<V102P$"% ,4
M    " ":GE-<]!C/:/8$  !]+P  %0              @ '7$P  >6-B9"TR
M,#(U,#DS,%]D968N>&UL4$L! A0#%     @ FIY37* 6]0IY"   O6   !4
M             ( ! !D  'EC8F0M,C R-3 Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( )J>4URY1JHYE@0  $XP   5              "  :PA  !Y8V)D+3(P
M,C4P.3,P7W!R92YX;6Q02P$"% ,4    " ":GE-<6#RB@6V2  "+I@0 %
M            @ %U)@  >6-B9#(P,C8P,C$X7W,Q82YH=&U02P4&      <
,!P"] 0  %+D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ycbd20260218_s1a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ycbd-20250930.xsd" xlink:type="simple"/>
    <context id="d_2024-10-01_2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001644903</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d_2024-10-01_2025-09-30" id="ixv-2731">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d_2024-10-01_2025-09-30" id="ixv-2732">0001644903</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d_2024-10-01_2025-09-30" id="c3">S-1/A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="d_2024-10-01_2025-09-30" id="c4">cbdMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2024-10-01_2025-09-30" id="c5">NC</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2024-10-01_2025-09-30" id="c6">47-3414576</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2024-10-01_2025-09-30" id="c7">2101 Westinghouse Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2024-10-01_2025-09-30" id="c8">Charlotte</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2024-10-01_2025-09-30" id="c9">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2024-10-01_2025-09-30" id="c10">28273</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2024-10-01_2025-09-30" id="c11">704</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2024-10-01_2025-09-30" id="c12">445-3060</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="d_2024-10-01_2025-09-30" id="c13">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2024-10-01_2025-09-30" id="c14">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2024-10-01_2025-09-30" id="c15">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="d_2024-10-01_2025-09-30" id="c16">The registrant hereby amends this registration statement on such date or date(s) as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until the registration statement shall become effective on such date as the SEC acting pursuant to said Section 8(a) may determine.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">cbdMD, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3414576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2101 Westinghouse Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Charlotte<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">28273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">445-3060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The registrant hereby amends this registration statement on such date or date(s) as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until the registration statement shall become effective on such date as the SEC acting pursuant to said Section 8(a) may determine.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001644903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>16</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ycbd20260218_s1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cbdmd.com/20250930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ycbd-20250930.xsd</File>
    <File>ycbd-20250930_def.xml</File>
    <File>ycbd-20250930_lab.xml</File>
    <File>ycbd-20250930_pre.xml</File>
    <File doctype="S-1/A" isOnlyDei="true" isUsgaap="true" original="ycbd20260218_s1a.htm">ycbd20260218_s1a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>smlogo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>23
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ycbd20260218_s1a.htm": {
   "nsprefix": "ycbd",
   "nsuri": "http://www.cbdmd.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "ycbd-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "ycbd-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ycbd-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ycbd-20250930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ycbd20260218_s1a.htm"
     ]
    }
   },
   "keyStandard": 16,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 27,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 16
   },
   "report": {
    "R1": {
     "role": "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2024-10-01_2025-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ycbd20260218_s1a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-10-01_2025-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ycbd20260218_s1a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AmendmentDescription",
        "terseLabel": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentType",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cbdmd.com/20250930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
